Compositions and methods for improving sample identification in indexed nucleic acid libraries

By blocking and modifying the ends of the polynucleotide, the problem of sequencing results confusion caused by index jumps is solved, and the identification accuracy of the polynucleotide library is improved.

CN110770353BActive Publication Date: 2024-11-26ILLUMINA INC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201880040485.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2017-04-23
Filing Date
2018-04-23
Publication Date
2024-11-26
Estimated Expiration
2039-04-03

AI Technical Summary

Technical Problem

In the existing polynucleotide sequencing technology, the index jump phenomenon leads to confusion in sequencing results, making it difficult to accurately identify the library source of polynucleotides.

Method used

During library sample preparation, the unincorporated adaptor 3' ends of the polynucleic acid are blocked and the 5' and 3' ends of the polynucleotide are modified to prevent exonuclease degradation and reduce the occurrence of index jumps.

Benefits of technology

It significantly reduces the index skip rate, improves the accuracy and reliability of sequencing results, and ensures the correct identification of polynucleotides.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN110770353B_ABST
    Figure CN110770353B_ABST
Patent Text Reader

Abstract

The present invention relates to compositions and methods for improving the rate of correct sample identification in indexed nucleic acid library preparations for multiplex next-generation sequencing by modifying or blocking the 5' and 3' ends of indexed polynucleotides pooled from multiple samples with optional exonuclease treatment prior to amplification and sequencing.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related Applications

[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 488,833, filed April 23, 2017, which is hereby incorporated by reference.

[0003] field

[0004] The present disclosure relates particularly to sequencing polynucleotides from multiple libraries; and more particularly, to increasing the likelihood that sequencing correctly identifies the library from which the polynucleotide originated.

[0005] background

[0006] Improvements in sequencing methodology have allowed the sequencing of pooled or multiplexed polynucleic acids from different libraries in a single sequencing protocol. Library-specific sequences ("index tags") can be added to the polynucleic acids of each library so that the origin of each sequenced polynucleic acid can be correctly identified. Index tag sequences can be added to the polynucleic acids of a library by, for example, ligating adapters containing the index tag sequences to the ends of the polynucleic acids.

[0007] The adapter may include sequences other than the index tag sequence, such as a universal extension primer sequence and a universal sequencing primer sequence. The universal extension primer sequence may be hybridized in particular with a first oligonucleotide coupled to a solid surface. The first oligonucleotide may have a free 3' end, and a polymerase may use the hybridized library polynucleotide as a template to add nucleotides from the free 3' end to extend the sequence, causing the reverse strand of the library polynucleotide to be coupled to a solid surface. Additional copies of the forward strand and the reverse strand may be coupled to a solid surface by cluster amplification. An example of cluster amplification is bridge amplification, in which the 3' end of the previously amplified polynucleotide bound to the solid surface is hybridized with a second oligonucleotide bound to the solid surface. The second oligonucleotide may have a free 3' end, and a polymerase may use the coupled reverse strand polynucleotide as a template to add nucleotides from the free 3' end to extend the sequence, causing the forward strand of the library polynucleotide to be coupled to a solid surface via a second oligonucleotide. The process may be repeated to produce clusters of forward strands and reverse strands coupled to a solid surface. Prior to sequencing, the forward strand or reverse strand may be removed, for example, by cleavage.

[0008] The sequencing primer can be hybridized with a portion of the polynucleotide chain coupled to the solid support. For example, the sequencing primer can be hybridized with a universal sequencing primer sequence (if present). Sequencing can be performed by adding nucleotides to the sequencing primer and detecting the identity of the added nucleotides using the coupled polynucleotide as a template in multiple rounds. The hybridization of the sequencing primer can occur at a position on the coupled polynucleotide chain to allow sequence identification of the index tag sequence and the target sequence of the polynucleotide coupled to the solid surface, or a separate sequencing primer can be used to sequence the index tag sequence and the target sequence separately. Therefore, the target sequence can be indexed to a specific library source based on the index tag sequence associated with the target sequence.

[0009] Although each polynucleic acid to be sequenced contains a library-specific index tag sequence, errors may occur in identifying the library source of the polynucleic acid being sequenced due to a phenomenon known as index hopping. When an index tag sequence from one library is inadvertently added to a polynucleic acid from another library, index hopping occurs. Index hopping may occur during library preparation or during cluster amplification of polynucleotides on a flow cell or other suitable solid support for sequencing. Index hopping may confuse the results of sequencing, such as causing improper designation of the library source of the polynucleotide being sequenced or discarding sequencing results.

[0010] Brief description

[0011] One or more aspects of the present disclosure address at least one potential mechanism associated with index jumping by blocking the 3' end of the polynucleotide including unincorporated adapters during library sample preparation. Without intending to be bound by theory, it is believed that index jumping may occur when an unincorporated adapter comprising an index tag sequence for one library hybridizes with a portion of an adapter from another library and the unincorporated adapter is used as a primer during cluster amplification. Therefore, a target sequence from one library can be tagged with an index tag from an adapter of another library. During subsequent multiple rounds of cluster amplification, additional copies of the target that was incorrectly tagged may be amplified before sequencing. Such index jumping may confuse the results of subsequent sequencing. By blocking the 3' end of the polynucleotide in the library including unincorporated adapters during library sample preparation, the ability of the unincorporated adapter to be used as a primer during cluster amplification will be blocked.

[0012] Additionally or alternatively, aspects of embodiments of the present disclosure relate to protecting the 5' and 3' ends of a template polynucleotide to be immobilized on a surface for sequencing from exonucleases and degrading the remaining unprotected polynucleotide to inhibit the ability of the unprotected polynucleotide to participate in index hopping.

[0013] In some aspects described herein, a method includes providing a first library comprising a first more than one polynucleotide having a first adapter-target-first adapter sequence. The polynucleotide of the first more than one polynucleotide is double-stranded in a region comprising at least a portion of the first adapter at both ends of the target and the first adapter. The method also includes providing a first primer oligonucleotide, the first primer oligomer being configured to hybridize with a portion of the first adapter near the 3' end of the chain of the first adapter. The 5' end of the first primer oligonucleotide is modified to prevent digestion by an enzyme with 5' exonuclease activity. The method also includes providing a second primer oligonucleotide, the second primer oligomer being configured to hybridize with a complementary sequence of a portion of the first adapter near the 3' end of the chain of the complementary sequence of the first adapter. The 5' end of the second primer oligonucleotide is modified to prevent digestion by an enzyme with 5' exonuclease activity. The method also includes incubating the first library with a first primer oligonucleotide and a second primer oligonucleotide in a solution under conditions suitable for amplifying a polynucleotide having a first adapter-target-first adapter sequence to produce an amplified first library polynucleotide having a 5' end modified to prevent digestion by an enzyme having 5' exonuclease activity. The amplified polynucleotide has an amplified first adapter-target-amplified first adapter sequence. The amplified first adapter sequence comprises a first library-specific sequence. The method also includes modifying the 3' end of the amplified first library polynucleotide to prevent one or both of (i) or (ii): (i) digestion by an enzyme having 3' exonuclease activity, or (ii) addition of nucleotides to the 3' end by an enzyme having polymerase activity, thereby producing a protected first library polynucleotide having a modified 5' end and a 3' end. Preferably, the 3' end is modified to inhibit the addition of nucleotides to the 3' end by an enzyme having polymerase activity.

[0014] Protected first library polynucleotides with modified 5' and 3' ends can be pooled with similar polynucleotides from other libraries and immobilized on a surface for sequencing. When the 3' end was modified to include a dideoxynucleotide, a nearly 100-fold reduction in index jumping was observed.

[0015] In some aspects described herein, the polynucleotide prepared for fixing for sequencing has an adapter-target-adapter sequence. The adapter sequence comprises a library-specific sequence. The polynucleotide is double-stranded in a region comprising at least a portion of the target and the adapter at both ends of the target. The 5' end and the 3' end of the polynucleotide in the region of the adapter sequence are single-stranded. The 5' end is modified to prevent digestion by an enzyme with 5' exonuclease activity. The 3' end is modified to inhibit one or both of (i) or (ii): (i) digestion by an enzyme with 3' exonuclease activity, or (ii) addition of nucleotides to the 3' end by an enzyme with polymerase activity. Preferably, the 3' end is modified to inhibit addition of nucleotides to the 3' end by an enzyme with polymerase activity.

[0016] In some embodiments, the composition comprises a polynucleotide and an exonuclease.

[0017] The methods, polynucleotides and compositions described herein can be used to mitigate index jumping, for example by blocking the 3' ends of polynucleotides, including unincorporated adapters, or degrading unblocked polynucleotides, including unincorporated adapters, during library sample preparation. If the adapter hybridizes to the adapter-target-adapter polynucleotide sequence during cluster amplification, by blocking the 3' ends of the unincorporated adapters, the unincorporated adapters cannot be extended during cluster amplification. Additionally or alternatively, those polynucleotides that are not blocked at the 3' ends can be degraded by exonucleases to mitigate index jumping.

[0018] Additional features and advantages of the subject matter of the present disclosure will be set forth in the detailed description that follows, and in part will be apparent to those skilled in the art from that description, or will be recognized by practicing the subject matter of the present disclosure as described herein, including the following detailed description, claims, and accompanying drawings.

[0019] It will be understood that the foregoing general description and the following detailed description both illustrate embodiments of the subject matter of the present disclosure and are intended to provide an overview or framework for understanding the nature and characteristics of the subject matter of the present disclosure as claimed therein. The accompanying drawings are included to provide a further understanding of the subject matter of the present disclosure and are incorporated into and constitute a part of this specification. The accompanying drawings illustrate multiple embodiments of the subject matter of the present disclosure and are used together with the description to explain the principles and operation of the subject matter of the present disclosure. Additionally, the drawings and descriptions are meant to be illustrative only and are not intended to limit the scope of the claims in any way. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] The following detailed description of specific embodiments of the present disclosure is best understood when read in conjunction with the following drawing figures.

[0022] Figure 1is a schematic diagram illustrating one embodiment of a method for generating a 5' modified and 3' blocked template polynucleotide.

[0023] Figure 2 is a schematic diagram of an embodiment of an adaptor according to aspects of the disclosure presented herein.

[0024] Figure 3 is a method according to aspects of the disclosure presented herein having an adapter-target-adapter sequence (which may include substantially Figure 2 Schematic diagram of an embodiment of a template polynucleotide having an adaptor (shown in ).

[0025] Figure 4 is a diagram illustrating the use of a template polynucleotide (which may be Figure 3 Schematic diagram of an embodiment of a cluster amplification process of an embodiment of the template polynucleotide depicted in .

[0026] Figure 5 is a schematic diagram illustrating an embodiment of how 3' end blocking can reduce index jumping.

[0027] Figure 6 is a schematic diagram illustrating an embodiment of how exonuclease treatment can reduce index hopping according to various embodiments described herein.

[0028] Fig. 7A and 7B The nature of the index jumping phenomenon is illustrated. Fig. 7A It shows how reads from a given sample can be incorrectly demultiplexed and mixed with different samples after demultiplexing. Figure 7B We demonstrate index jumping in a dual-index system, where the index jumps lead to unexpected combinations of index label sequences.

[0029] Fig. 8A and 8B A general method for measuring the index jump rate in a given system is illustrated. Fig. 8A An exemplary layout of a dual adaptor plate is shown, where each individual well of a 96-well plate contains a unique pair of index tag sequences. Figure 8B Shown is the experimental setup designed to measure the index jump rate, where only unique dual-index tag combinations are used.

[0030] Fig. 9A and 9B The effect of unligated adaptors on index hopping rate is shown. Fig. 9A A 6-fold increase in the index jump associated with 50% spike-in of free adaptor is shown. Fig. 9B The effect of free forked adapters on index jump rate is shown to be approximately linear over the range tested.

[0031] Fig.10 Shown in Illumina The effect of combined exonuclease and 3' blocking treatment on index jump rate in a Nano(PCR) library preparation workflow, comparing the performance of standard adapters and PCR-protected adapters according to the present invention.

[0032] The schematic diagrams are not necessarily to scale. The same numbers used in the drawings refer to similar components, steps, etc. However, it will be understood that the use of a number to refer to a component in a given figure is not intended to limit the use of the same number to label that component in another figure. In addition, the use of different numbers to refer to multiple components is not intended to indicate that the differently numbered components cannot be the same or similar to the other numbered components.

[0033] Detailed Description

[0034] Reference will now be made in greater detail to various embodiments of the subject matter of the present disclosure, some of which are illustrated in the accompanying drawings.

[0035] definition

[0036] Unless otherwise indicated, all scientific and technical terms used herein have the meanings commonly used in the art. The definitions provided herein are to facilitate understanding of certain terms frequently used herein and are not meant to limit the scope of the present disclosure.

[0037] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to an "index tag sequence" includes instances of having two or more such "index tag sequences," unless the context clearly dictates otherwise.

[0038] As used in this specification and the appended claims, the term "or" is generally used in its sense including "and / or" unless the context clearly dictates otherwise. The term "and / or" means one or all of the listed elements or any combination of two or more of the listed elements. The use of "and / or" in some contexts does not imply that the use of "or" in other contexts may not mean "and / or".

[0039] As used herein, “have,” “has,” “having,” “include,” “includes,” “including,” “comprise,” “comprises,” “comprising,” and the like are used in their open, inclusive sense, and generally mean “include, but not limited to,” “includes, but not limited to,” or “including, but not limited to.”

[0040] "Optional" or "optionally" means that the subsequently described event, circumstance or component may or may not occur, and that the description includes instances where the event, circumstance or component occurs and instances where it does not.

[0041] The words "preferred" and "preferably" refer to embodiments of the present disclosure that may provide certain benefits under certain circumstances. However, other embodiments may also be preferred under the same or other circumstances. In addition, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the present invention.

[0042] Also herein, numerical ranges recited by endpoints include all numbers contained in that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.). Where a range of values ​​is "greater than," "less than," etc. a particular value, the value is included in the range.

[0043] Unless otherwise expressly stated, it is not intended that any method described herein be construed as requiring that its steps be performed in a specific order. Therefore, in the event that a method claim does not actually recite the order in which its steps are to be followed or does not otherwise specifically state in the claims or specification that the steps are to be limited to a specific order, no specific order is intended to be inferred. Any recited single or multiple features or aspects in any one claim may be combined or arranged with any other recited features or aspects in any other one or more claims.

[0044] Although the transitional phrase "comprising" may be used to disclose various features, elements, or steps of a particular embodiment, it will be understood that alternative embodiments are implied, including those that may be described using the transitional phrase "consisting" or "consisting essentially of." Thus, for example, implicit alternative embodiments of a polynucleotide comprising an adaptor-target-adaptor sequence include embodiments in which the polynucleotide consists of an adaptor-target-adaptor sequence and embodiments in which the polynucleotide consists essentially of an adaptor-target-adaptor sequence.

[0045] As used herein, "providing" in the context of a polynucleotide, composition or article means preparing the polynucleotide, composition or article, purchasing the polynucleotide, composition or article, or otherwise obtaining the compound, composition or article.

[0046] As used herein, "amplify," "amplifying," or "amplification reaction," and their derivatives, generally refer to any action or process by which at least a portion of a polynucleotide (e.g., a template polynucleotide) is replicated or copied into at least one additional polynucleotide. The additional polynucleotide optionally includes a sequence that is substantially identical or substantially complementary to at least a portion of the template polynucleotide. The template polynucleotide may be single-stranded or double-stranded, and the additional polynucleotide may be independently single-stranded or double-stranded. Amplification optionally includes linear or exponential replication of the polynucleotide. In some embodiments, such amplification may be performed using isothermal conditions; in other embodiments, such amplification may include thermal cycling. In some embodiments, amplification is a multiplex amplification, which includes simultaneously amplifying more than one target sequence in a single amplification reaction. In some embodiments, "amplification" includes amplification based on at least a portion of a separate DNA nucleic acid and at least a portion of an RNA nucleic acid, or a combination thereof. The amplification reaction may include any amplification process known to those of ordinary skill in the art. In some embodiments, the amplification reaction includes a polymerase chain reaction (PCR).

[0047] As used herein, the term "polymerase" is intended to be consistent with its use in the art, and includes enzymes that, for example, use a polynucleotide as a template strand to produce a complementary replica of a polynucleotide. Typically, a DNA polymerase binds to a template strand and then moves downstream along the template strand, sequentially adding nucleotides to the free hydroxyl groups at the 3' end of the growing strand of the nucleic acid. DNA polymerases typically synthesize complementary DNA molecules from a DNA template, and RNA polymerases typically synthesize RNA molecules (transcription) from a DNA template. Polymerases can use short RNA or DNA chains known as primers to start chain growth. Some polymerases can displace the chain upstream of a site where a base is added to one of its chains. Such polymerases are referred to as chain displacement, meaning that they have the activity of removing complementary strands from a template strand read by a polymerase. Exemplary polymerases with chain displacement activity include, but are not limited to, large fragments of Bst (Bacillus stearothermophilus) polymerase, exo-Klenow polymerase, or sequencing-grade T7 exo-polymerases. Some polymerases degrade the strands in front of them, effectively replacing the strands in front with the growing strands behind (5' exonuclease activity). Some polymerases have activity that degrades the strand behind them (3' exonuclease activity). Some useful polymerases have been modified by mutation or otherwise to reduce or eliminate 3' exonuclease activity and / or 5' exonuclease activity.

[0048] As defined herein, "multiplex amplification" refers to the selective and non-random amplification of two or more target sequences in a sample using at least one target-specific primer. In some embodiments, multiple amplification is performed so that some or all of the target sequences are amplified in a single reaction vessel. The "plexy" or "plex" of a given multiple amplification generally refers to the number of different target-specific sequences amplified during the single multiple amplification. In some embodiments, the multiplicity can be about 12-, 24-, 48-, 96-, 192-, 384-, 768-, 1536-, 3072-, 6144- or higher. It is also possible to detect the amplified target sequence by several different methods (e.g., gel electrophoresis followed by density determination (densitometry), quantitatively measured with a bioanalyzer or quantitative PCR, hybridized with labeled probes; incorporation of biotinylated primers followed by avidin-enzyme conjugate detection; 32P-labeled deoxynucleotide triphosphates are incorporated into the amplified target sequence).

[0049] As used herein, the term "primer" and its derivatives generally refer to any polynucleotide that can hybridize with a target sequence of interest. Generally, primers act as substrates to which nucleotides can be polymerized by polymerases; however, in some embodiments, primers can become incorporated into a synthetic nucleic acid chain and provide a site to which another primer can hybridize to initiate the synthesis of a new chain complementary to a synthetic nucleic acid molecule. Primers can include any combination of nucleotides or their analogs. In some embodiments, primers are single-stranded oligonucleotides or polynucleotides. The terms "polynucleotide" and "oligonucleotide" are used interchangeably herein to refer to a polymeric form of nucleotides of any length, and may include ribonucleotides, deoxyribonucleotides, their analogs, or mixtures thereof. The term refers only to the primary structure of a molecule. Therefore, the term includes triple-stranded, double-stranded, and single-stranded deoxyribonucleic acids ("DNA"), as well as triple-stranded, double-stranded, and single-stranded ribonucleic acids ("RNA"). As used herein, "amplified target sequence" and its derivatives generally refer to a polynucleotide sequence generated by amplifying a target sequence using a target-specific primer and the method provided herein. The amplified target sequence can have the same sense sequence (ie, positive strand) or antisense sequence (ie, negative strand) relative to the target sequence.

[0050] As used herein, the terms "ligating," "ligation," and their derivatives generally refer to the process of covalently linking two or more molecules together, such as covalently linking two or more polynucleotides to each other. In some embodiments, the connection includes a nick between adjacent nucleotides of the connecting polynucleotides. In some embodiments, the connection includes forming a covalent bond between the end of a first polynucleotide and the end of a second polynucleotide. In some embodiments, the connection may include forming a covalent bond between a 5' phosphate group of one nucleic acid and a 3' hydroxyl group of a second nucleic acid, thereby forming a connected polynucleotide. Generally for the purposes of the present disclosure, an amplified target sequence may be linked to an adaptor to produce an adaptor-linked amplified target sequence.

[0051] As used herein, "ligase" and its derivatives generally refer to any agent capable of catalyzing the connection of two substrate molecules. In some embodiments, ligases include enzymes capable of catalyzing the connection of nicks between adjacent nucleotides of a nucleic acid. In some embodiments, ligases include enzymes capable of catalyzing the formation of a covalent bond between a 5' phosphate of a nucleic acid molecule and a 3' hydroxyl of another nucleic acid molecule to form a connected nucleic acid molecule. Suitable ligases may include, but are not limited to, T4 DNA ligase, T4 RNA ligase, and E. coli DNA ligase.

[0052] As used herein, "connection conditions" and their derivatives generally refer to conditions suitable for connecting two molecules to each other. In some embodiments, the connection conditions are suitable for closing the nick or gap between nucleic acids. As used herein, the term nick or gap is consistent with the use of the term in the art. Typically, the nick or gap can be connected at an appropriate temperature and pH in the presence of an enzyme such as a ligase. In some embodiments, T4 DNA ligase can connect the nick between nucleic acids at a temperature of about 70°C-72°C.

[0053] As used herein, the term "universal sequence" refers to a region of a sequence common to two or more nucleic acid molecules, wherein these molecules also have regions of sequences that are different from each other. Universal sequences present in different members of a set of molecules can allow a population of universal capture nucleic acids complementary to the universal sequence to capture multiple different nucleic acids. Similarly, universal sequences present in different members of a set of molecules can allow a population of universal primers complementary to the universal sequence to replicate or amplify multiple different nucleic acids. Therefore, universal capture polynucleotides or universal primers include sequences that can specifically hybridize with universal sequences. Polynucleotides can be modified to attach universal adapters, for example, at one or both ends of different sequences.

[0054] Index Jump

[0055] The present disclosure relates particularly to sequencing of nucleic acids from multiple indexed libraries; more particularly, to increasing the likelihood that sequencing correctly identifies the library from which the nucleic acid originated.

[0056] When polynucleotides from different libraries are pooled or multiplexed for sequencing, the polynucleotides from each library can be modified to contain a library-specific index tag sequence. During sequencing, the index tag is sequenced together with the target polynucleotide sequence from the library. Thus, the index tag sequence can be associated with the target polynucleotide sequence so that the library from which the target sequence originated can be identified.

[0057] However, a phenomenon known as index hopping may occur in a small percentage of sequence results (typically 0.5% to 2%). Index hopping is when an index tag sequence from one library associates with a target polynucleotide from another library (see Fig. 7A and 7B ). Although the mechanism by which index jumping may occur is not fully understood, the rate of index jumping can be effectively reduced by blocking the 3' ends of unincorporated adapters after the adapters are attached to the target polynucleotides of the library, especially after the index tag sequence is attached to the polynucleotide.

[0058] Initial library sample preparation

[0059] A library comprising polynucleotides can be prepared in any suitable manner by attaching oligonucleotide adapters to target polynucleotides. As used herein, a "library" is a population of polynucleotides from a given source or sample. A library comprises more than one target polynucleotide. As used herein, a "target polynucleotide" is a polynucleotide that is desired to be sequenced. The target polynucleotide can be substantially any polynucleotide whose sequence is known or unknown. For example, the target polynucleotide can be a fragment of genomic DNA or cDNA. Sequencing can result in determination of the sequence of all or part of the target polynucleotide. The target polynucleotide can be derived from an initial polynucleotide sample that has been randomly fragmented. The target polynucleotide can be processed into a template suitable for amplification by placing a universal primer sequence at the end of each target fragment. The target polynucleotide can also be obtained by reverse transcription into cDNA from an initial RNA sample.

[0060] The terms "polynucleotide" and "oligonucleotide" are used interchangeably herein to refer to a polymeric form of nucleotides of any length, and may include ribonucleotides, deoxyribonucleotides, analogs thereof, or mixtures thereof. The term refers only to the primary structure of the molecule. Thus, the term includes triple-stranded, double-stranded, and single-stranded deoxyribonucleic acids ("DNA"), and triple-stranded, double-stranded, and single-stranded ribonucleic acids ("RNA"). The terms polynucleotide and oligonucleotide as used herein also include cDNA, which is a complementary or copy DNA produced from an RNA template, for example, by the action of a reverse transcriptase.

[0061] The initial polynucleotide molecule may be derived from a double-stranded DNA (dsDNA) form (e.g., genomic DNA fragments, PCR and amplification products, etc.), or may be derived from a single-stranded form of DNA or RNA and converted to a dsDNA form. For example, mRNA molecules may be copied into double-stranded cDNA using standard techniques well known in the art. The precise sequence of the initial polynucleotide is generally unimportant to the disclosure presented herein, and may be known or unknown.

[0062] In some embodiments, the initial target polynucleotide is an RNA molecule. In one aspect of such an embodiment, the RNA separated from a particular sample is first converted into double-stranded DNA using techniques known in the art. The double-stranded DNA can then be indexed and labeled with library-specific tags. Different preparations of such double-stranded DNA comprising library-specific index tags can be produced in parallel by RNA isolated from different sources or samples. Subsequently, different preparations of double-stranded DNA comprising different library-specific index tags can be mixed, all sequenced, and according to the presence of library-specific index tag sequences, the identity of each sequenced fragment is determined relative to the library separated / sourced from other.

[0063] In some embodiments, the initial target polynucleotide is a DNA molecule.For example, the initial polynucleotide can represent the entire genetic complementary sequence of an organism, and is a genomic DNA molecule, such as a human DNA molecule, which includes both introns and exon sequences (coding sequences), and non-coding regulatory sequences such as promoters and enhancer sequences.Although it is conceivable that a specific subset of a polynucleotide sequence or genomic DNA can also be used, such as, for example, a specific chromosome or a part thereof.In many embodiments, the sequence of the initial polynucleotide is unknown.Can be before or after a fragmentation process such as a random fragmentation process, and before, during or after connecting an adapter oligonucleotide, by chemical method or enzyme method process DNA target polynucleotide.

[0064] Preferably, the initial target polynucleotide is fragmented into a suitable length suitable for sequencing. The target polynucleotide can be fragmented in any suitable manner. Preferably, the target polynucleotide is randomly fragmented. Random fragmentation refers to that polynucleotide is fragmented in a disordered manner by, for example, enzymatic, chemical or mechanical means. Such fragmentation methods are known in the art, and standard methods (Sambrook and Russell, Molecular Cloning, A Laboratory Manual, 3rd edition) are used. For the sake of clarity, the smaller fragments of larger pieces of polynucleotides are amplified by specific PCR to produce such smaller fragments that are not equivalent to the larger pieces of nucleotides of fragmentation, because the larger pieces of polynucleotides remain intact (that is, not fragmented by PCR amplification). In addition, random fragmentation is designed to produce a fragment that does not consider the sequence identity or position of the nucleotides comprising fracture and / or near the fracture.

[0065] In some embodiments, random fragmentation is by mechanical means such as nebulization or sonication to produce fragments of about 50 base pairs in length to about 1500 base pairs in length, such as 50-700 base pairs in length or 50-500 base pairs in length.

[0066] Fragmentation of polynucleotide molecules by mechanical means (e.g., atomization, sonication, and Hydroshear) may result in fragments with a heterogeneous mixture of flat ends and 3'-overhanging ends and 5'-overhanging ends. The ends of the fragments can be repaired using methods known in the art or kits (such as the Lucigen DNA terminator end repair kit) to produce ends that are optimal for insertion, for example, into a flat site of a cloning vector. In some embodiments, the ends of the fragments of a population of nucleic acids are flat-ended. The ends of the fragments can be flat-ended and phosphorylated. The phosphate moiety can be introduced by enzymatic treatment, for example, using a polynucleotide kinase.

[0067] In some embodiments, the target polynucleotide is prepared to have a single overhanging nucleotide by, for example, the activity of certain types of DNA polymerases such as Taq polymerase or Klenow exominus polymerase (having non-template-dependent terminal transferase activity, adding a single deoxynucleotide, such as deoxyadenosine (A), to, for example, the 3' end of a PCR product). Such an enzyme can be used to add a single nucleotide "A" to the 3' end of the blunt end of each strand of the target polynucleotide duplex. Thus, by reacting the target polynucleotide duplex with Taq polymerase or Klenow exo minus polymerase, "A" can be added to the 3' end of each end-repaired duplex strand, and the adapter polynucleotide construct can be a compatible T-construct with the "T" overhang present at the 3' end of each duplex region of the adapter construct. This terminal modification also prevents self-ligation of the target polynucleotide, so that there is a bias towards forming a combined connected adapter-target polynucleotide.

[0068] In some embodiments, fragmentation is accomplished by tagmentation as described in, for example, International Patent Application Publication WO2016 / 130704. In such a method, double-stranded polynucleotides are fragmented using transposase, and universal primer sequences are attached to one chain of the double-stranded polynucleotides. The resulting molecule can be filled with gaps and undergo extension, such as by PCR amplification, using primers comprising 3' ends hybridized with the universal primer sequences attached and 5' ends of other sequences comprising adapters, or using primers comprising 3' ends hybridized with the complementary sequences of the universal primer sequences attached and 5' ends of other sequences comprising adapters.

[0069] The adapter or a portion of the adapter can be attached to the target polynucleotide in any other suitable manner. In some embodiments, the adapter is introduced in a multi-step process, such as a two-step process, including connecting a portion of the adapter to a target polynucleotide with a universal primer sequence. The second step includes extension, such as by PCR amplification, using a primer comprising a 3' end hybridized with the attached universal primer sequence (or hybridized with the complementary sequence of the universal primer sequence) and a 5' end of other sequences comprising the adapter. For example, such extension can be performed as described in U.S. Patent No. 8,053,192. Additional extension can be performed to provide additional sequences to the 5' end of the resulting previously extended polynucleotide.

[0070] In some embodiments, the entire adapter is connected to the fragmented target polynucleotide. The adapter connected includes a double-stranded region connected to a double-stranded target polynucleotide. Preferably, the double-stranded region is as short as possible without losing function. In this context, "function" refers to the ability of the double-stranded region to form a stable duplex under standard reaction conditions. In some embodiments, standard reaction conditions refer to the reaction conditions for the polynucleotide ligation reaction catalyzed by an enzyme, which will be well known to the skilled reader (for example, incubated in a connection buffer suitable for an enzyme at a temperature in the range of 4 ° C to 25 ° C), so that the two chains forming the adapter are partially annealed during the adapter is connected to the target molecule. Connection methods are known in the art, and standard methods (Sambrook and Russell, Molecular Cloning, A Laboratory Manual, the third edition) can be used. Such methods use ligases such as DNA ligases to achieve or catalyze the connection of the ends of the two polynucleotide chains of the adapter duplex oligonucleotide and the target polynucleotide duplex in this case, so that covalent connection is formed. The adapter duplex oligonucleotide can include a 5'-phosphate moiety to facilitate connection to the target polynucleotide 3'-OH. The target polynucleotide may include a 5'-phosphate moiety remaining from the shearing process or added using an enzymatic treatment step, and has been end-repaired, and optionally extended by one or more protruding bases to give a 3'-OH suitable for connection. In this article, attachment means the covalent connection of a polynucleotide chain that has not been covalently connected before. In a specific aspect of the present invention, such attachment occurs by forming a phosphodiester bond between two polynucleotide chains, but other means of covalent connection (e.g., non-phosphodiester backbone connection) can be used. Adapters are connected to target polynucleotides in more detail in, for example, U.S. Patent No. 8,053,192.

[0071] Whether the entire adapter or a portion of the adapter is attached to the double-stranded target fragment, the adapter or portion comprises a double-stranded region and a region comprising two non-complementary single strands. The double-stranded region of the adapter can have any suitable number of base pairs. Preferably, the double-stranded region is a short double-stranded region formed by annealing of two partially complementary polynucleotide chains, typically comprising 5 or more continuous base pairs. This "double-stranded region" of the adapter refers to the region where the two chains anneal, and does not imply any specific structural conformation. In some embodiments, the double-stranded region comprises 20 or less continuous base pairs, such as 10 or less or 5 or less continuous base pairs.

[0072] The stability of the double stranded region may be increased by including non-natural nucleotides that exhibit stronger base pairing than standard Watson-Crick base pairs, and thus its length may be reduced. Preferably, the two strands of the adaptor are 100% complementary in the double stranded region.

[0073] When the adaptor is attached to the target polynucleotide, the non-complementary single-stranded region can form the 5' end and the 3' end of the polynucleotide to be sequenced. The term "non-complementary single-stranded region" refers to a region of the adaptor where the sequences of the two polynucleotide chains forming the adaptor exhibit a degree of non-complementarity such that the two chains are unable to completely anneal to each other under standard annealing conditions used for PCR reactions.

[0074] The non-complementary single-stranded region is provided by the different parts of the identical two polynucleotide chains forming the double-stranded region. The lower limit of the length of the single-stranded portion will be determined by the function of the suitable sequence of the combination of the primers for primer extension, PCR and / or sequencing, for example. In theory, there is no upper limit of the length of the region that does not match, except that the total length of the adapter is usually minimized, for example, to promote that the unbound adapter is separated from the adapter-target construct after one or more attachment steps is advantageous. Therefore, it is usually preferred that the non-complementary single-stranded region length of the adapter is 50 or less continuous nucleotides, such as a length of 40 or less, 30 or less or 25 or less continuous nucleotides.

[0075] After the adapter or a portion of the adapter is attached to the target polynucleotide, the resulting polynucleotide can undergo a clean-up process to enhance the purity of the adapter-target-adapter polynucleotide by removing at least a portion of the unincorporated adapter. Any suitable clean-up process can be used, such as electrophoresis, size exclusion chromatography, etc. In some embodiments, solid phase reverse immobilization (SPRI) paramagnetic beads can be used to separate the adapter-target-adapter polynucleotide from the unattached adapter. Although such a method can enhance the purity of the resulting adapter-target-adapter polynucleotide, some unattached adapter oligonucleotides may be retained.

[0076] As used herein, "attached" or "bound" are used interchangeably in the context of an adaptor relative to a target sequence. As described above, the adaptor can be attached to the target polynucleotide using any suitable process. For example, the adaptor can be attached to the target by: by ligation with a ligase; by a combination of ligation of a portion of the adaptor and addition of the other or remaining portion of the adaptor by extension, such as PCR, with a primer containing the other or remaining portion of the adaptor; by transposition to incorporate a portion of the adaptor and by extension, such as PCR, with a primer containing the other or remaining portion of the adaptor to add the other or remaining portion of the adaptor; etc. Preferably, the attached adaptor oligonucleotide is covalently bound to the target polynucleotide.

[0077] Amplification

[0078] The polynucleotide resulting from attachment of the adaptor or a portion of the adaptor to the double stranded target is then subjected to amplification with primers having 5' ends that are modified to prevent digestion by an enzyme having 5' exonuclease activity.

[0079] The 5' end of the primer can be modified in any suitable manner to prevent digestion by an enzyme with 5' exonuclease activity. For the purposes of this disclosure, the modification that "prevents" digestion by exonucleases suppresses the activity of exonucleases relative to the action of exonucleases on unmodified ends. Preferably, the modification that prevents digestion by exonucleases eliminates the ability of exonucleases to digest polynucleotide chains. In some embodiments, the 5' end of the primer comprises a phosphorothioate bond. Preferably, the bond between the terminal three nucleotides of the 5' end of the primer comprises a phosphorothioate bond. For the purposes of this disclosure, the end of a polynucleotide whose bond between the terminal three nucleotides comprises a phosphorothioate bond can be referred to as an end comprising three phosphorothioate bonds. As is well known in the art, a phosphorothioate bond can be introduced into the 5' end of a polynucleotide in any suitable manner. Oligonucleotides comprising terminal phosphorothioate bonds can be purchased from many commercial suppliers, including, for example, Integrated DNA Technologies and Sigma-Aldrich.

[0080] If the adaptor attached to the target is only a portion of the adaptor prior to amplification, the remainder of the adaptor can be provided by the 5' end of the primer.

[0081] In either case, the first primer oligonucleotide with a modified 5' end for amplification is configured to hybridize with a portion of the adapter or adapter portion near the 3' end of the chain of the adapter or adapter portion. The second primer oligonucleotide with a modified 5' end for amplification is configured to hybridize with the complementary sequence of a portion of the adapter or adapter portion near the 3' end of the chain of the complementary sequence of the adapter or adapter portion. The complementary sequence of the adapter can be obtained by extending the first primer using the adapter-target-adapter as a template. After the complementary sequence is formed, the second adapter can hybridize with the complementary sequence.

[0082] The first primer and the second primer can be incubated with a polynucleotide resulting from attaching an adaptor or a portion of an adaptor to a double-stranded target ("adaptor-target-adaptor" polynucleotide) under conditions suitable for amplifying the adaptor-target-adaptor polynucleotide to produce a polynucleotide of an amplified adaptor-target-amplified adaptor sequence having a modified 5' end. If the adaptor-target-adaptor polynucleotide comprises the entire adaptor, the adaptor-target-adaptor polynucleotide may have the same sequence as the amplified adaptor-target-amplified adaptor sequence. If the adaptor-target-adaptor polynucleotide comprises only a portion of the adaptor, the amplified adaptor-target-amplified adaptor sequence will have additional nucleotides at the single-stranded end of the amplified adaptor sequence due to the addition of the remainder of the adaptor sequence from the primers.

[0083] As used herein, "conditions suitable for amplification" and its derivatives generally refer to conditions suitable for amplifying one or more polynucleotide sequences. Such amplification can be linear or exponential. In some embodiments, the amplification conditions may include isothermal conditions, or may alternatively include thermal cycling conditions, or a combination of isothermal and thermal cycling conditions. In some embodiments, conditions suitable for amplifying one or more polynucleotide sequences include polymerase chain reaction (PCR) conditions. Generally, amplification conditions refer to a reaction mixture sufficient to amplify polynucleotides such as one or more target sequences, or to amplify amplified target sequences connected to one or more adapters, such as amplified target sequences connected to adapters. Generally, amplification conditions include a catalyst for amplification or for polynucleotide synthesis, such as a polymerase; a primer having a certain degree of complementarity with the nucleic acid to be amplified; and nucleotides, such as deoxyribonucleotide triphosphates (dNTPs), to promote the extension of the primer after hybridization with the nucleic acid. Amplification conditions may require hybridization or annealing of primers to nucleic acids, extension of primers, and denaturation steps, in which the extended primers are separated from the polynucleotide sequences undergoing amplification. Typically, but not necessarily, amplification conditions may include thermal cycling; in some embodiments, amplification conditions include more than one cycle in which the steps of annealing, extension, and separation are repeated. Typically, amplification conditions include cations such as Mg++ or Mn++ and may also include a variety of ionic strength aids.

[0084] As used herein, the term "polymerase chain reaction" ("PCR") refers to the method of K.B. Mullis U.S. Pat. Nos. 4,683,195 and 4,683,202, which describe a method for increasing the concentration of a segment of a polynucleotide of interest in a mixture of genomic DNA without cloning or purification. This method for amplifying a polynucleotide of interest consists of introducing a large excess of two oligonucleotide primers into a DNA mixture containing the desired polynucleotide of interest, followed by a series of thermal cycles in the presence of a DNA polymerase. The two primers are complementary to the strands of the double-stranded polynucleotide of interest corresponding to them. The mixture is first denatured at a higher temperature, and then the primers are annealed to the complementary sequences within the polynucleotide of the molecule of interest. After annealing, the primers are extended with a polymerase to form a new pair of complementary chains. The steps of denaturation, primer annealing, and polymerase extension can be repeated many times (referred to as thermal cycling) to obtain a high concentration of amplified segments of the desired polynucleotide of interest. The length of the amplified segment (amplicon) of the desired polynucleotide of interest is determined by the relative position of the primers relative to each other, and therefore the length is a controllable parameter. Due to the repetition of this process, the method is referred to as "polymerase chain reaction" (hereinafter referred to as "PCR"). Because the amplified segments of the desired polynucleotide of interest become the main nucleic acid sequences (in terms of concentration) in the mixture, they are referred to as "PCR amplified". When modifying the method discussed above, more than one different primer pair can be used, and in some cases, one or more primer pairs are used for each polynucleotide of interest, thereby forming a multiplex PCR reaction to PCR amplify the polynucleotide.

[0085] Amplification of the adapter-target-adapter polynucleotide with a 5' modified primer produces a polynucleotide of an amplified adapter-target-amplified adapter sequence having a modified 5' end.

[0086] The resulting amplified adaptors contain the library-specific index tag sequence.Thus, the index tag itself is not formed from a portion of the target polynucleotide, but becomes part of the template used for amplification on a solid surface for sequencing.

[0087] Preferably, the index tag sequence length is 20 nucleotides or less. For example, the index tag sequence length can be 1-10 nucleotides or 4-6 nucleotides. Tetranucleotide index tags provide the possibility of multiplexing 256 samples on the same array, and hexanucleotide index tags enable processing of 4096 samples on the same array.

[0088] Amplified adapters can contain more than one index tag, allowing for increased multiplexing possibilities.

[0089] The library-specific index tag sequence can be located in the single-stranded region, double-stranded region, or spans the single-stranded and double-stranded regions of the adaptor. Preferably, the index tag sequence is in the single-stranded region of the adaptor.

[0090] The library-specific index tag sequence can be included on one or both 5' modified primers, or can be included in a portion of the adapter attached to the template fragment. If the library-specific index tag sequence is not included in the primer but is included in the portion of the adapter attached to the template fragment (and the primer adds the remainder of the adapter), adapter-target-adapter polynucleotides from different libraries can be pooled to amplify the amplified adapter-target-amplified adapter polynucleotide. If the primers include a library-specific index tag sequence, then each library should be amplified separately before pooling.

[0091] In any case, the amplified adapter can include any other suitable sequence except the index tag sequence. For example, the amplified adapter can include a universal extension primer sequence, which is generally located at the 5' end or 3' end of the amplified adapter and the resulting template polynucleotide for sequencing. The universal extension primer sequence can be hybridized with a complementary primer bound to a solid substrate surface. The complementary primer includes a free 3' end, and a polymerase or other suitable enzyme can use the hybridized library polynucleotide as a template to add nucleotides from the free 3' end to extend the sequence, resulting in the reverse strand of the library polynucleotide being coupled to a solid surface. Such an extension can be part of a sequencing run or cluster amplification.

[0092] In some embodiments, the amplified adaptors include one or more universal sequencing primer sequences. The universal sequencing primer sequences can be combined with sequencing primers to allow sequencing of the index tag sequence, the target sequence, or both the index tag sequence and the target sequence.

[0093] The precise nucleotide sequence of the amplified adapters is generally not critical to the invention and can be selected by the user such that the desired sequence elements are ultimately included in the consensus sequence of a template library obtained from the amplified adapters, which, for example, provide binding sites for a particular set of universal extension primers and / or sequencing primers.

[0094] It will be understood that "adapter-target-adapter sequence" or its equivalent refers to the orientation of the adaptors relative to each other and to the target, and does not necessarily mean that the sequence cannot include additional sequences, such as, for example, linker sequences.

[0095] Additional libraries can be prepared in a similar manner, each library comprising at least one library-specific index tag sequence or combination of index tag sequences that is different from index tag sequences or combinations of index tags from other libraries.

[0096] The resulting template polynucleotide having an amplified adapter-template-amplified adapter sequence may be subjected to a clean-up process such as described above.

[0097] The resulting adaptor-target-adaptor polynucleotide, whether or not it has first undergone cleanup, is 3' blocked along with any unincorporated primer oligonucleotide or remaining polynucleotide species.

[0098] 3' Block

[0099] 3' blocking can be performed on each library individually, or on the pooled library. Preferably, 3' blocking is performed on the pooled library.

[0100] 3' closed means that the polynucleotide is modified to prevent nucleotide incorporation at the 3' end so that the polynucleotide extends from the 3' end, or to prevent digestion by an enzyme with 3' exonuclease activity. Preferably, the 3' end is closed to prevent nucleotide incorporation at the 3' end so that the polynucleotide extends from the 3' end. More preferably, the 3' end is closed to prevent nucleotide incorporation at the 3' end so that the polynucleotide extends from the 3' end, and to prevent digestion by an enzyme with 3' exonuclease activity.

[0101] In some embodiments, the 3'-OH blocking group may be removable, such that the 3' carbon atom has been attached to a group of the structure -O-Z, wherein Z is any of -C(R')2-O-R", -C(R')2-N(R")2, -C(R')2-N(H)R", -C(R')2-S-R", and -C(R')2-F, wherein each R" is a removable protecting group or a portion of a removable protecting group; each R' is independently is a hydrogen atom, an alkyl, substituted alkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, acyl, cyano, alkoxy, aryloxy, heteroaryloxy or amide group, or a detectable label attached via a linker; or (R′)2 represents an alkylene group of formula ═C(R′″)2, wherein each R′″ may be the same or different and is selected from the group comprising hydrogen and halogen atoms and alkyl groups; and wherein the molecules may react to produce intermediates wherein each R ″ is exchanged for H, or where Z is —C(R′)2—F, F is exchanged for OH, SH or NH2, preferably for OH, wherein the intermediate dissociates under aqueous conditions to provide a molecule with a free 3'OH; provided that when Z is —C(R′)2—S—R″, both R′ groups are not H. In the case where the blocking group is —C(R′)2—O—R″, —C(R′)2—N(R″)2, —C(R′)2—N(H)R″, —C(R′)2—S— In any case of —R″ and —C(R′)2—F, that is, in any case of formula Z, each R′ may independently be H or an alkyl group. Preferably, Z is any one of the formulas —C(R′)2—O—R″, —C(R′)2—N(R″)2, —C(R′)2—N(H)R″ and —C(R′)2—SR″. Particularly preferably, Z has the formulas —C(R′)2—O—R″, —C(R′)2—N(R″)2 and —C(R′)2—SR″. R" can be a benzyl group or a substituted benzyl group. An example of a group of the structure -O-Z (wherein Z is -C(R')2-N(R")2) is one in which -N(R")2 is an azido group (-N3). One such example is azidomethyl, where each R' is H. Alternatively, R' in the Z group of the formula -C(R')2-N3 and other Z groups can be any other group discussed herein. Examples of typical R' groups include C 1-6Alkyl, particularly methyl and ethyl. Other non-limiting examples of suitable 3' blocking groups are provided in: Greene et al. "Protective Groups in Organic Synthesis," John Wiley & Sons, New York (1991), U.S. Pat. Nos. 5,990,300, 5,872,244, 6,232,465, 6,214,987, 5,808,045, 5,763,594, 7,057,026, 7,566,537, 7,785,796, 8,148,064, 8,394,586, 9,388,463, 9,410,200, 7,427,673, 7,772,384 No. 8,158,346, No. 9,121,062, No. 7,541,444, No. 7,771,973, No. 8,071,739, No. 8,597,881, No. 9,121,060, No. 9,388,464, No. 8,399,188, No. 8,808,988, No. 9,051,612, No. 9,469,873 and U.S. Publication Nos. 2016 / 0002721 and 2016 / 0060692, the entire contents of which are incorporated herein by reference.

[0102] 3' blocking can be accomplished in any suitable manner. For example, a blocking moiety can be covalently attached to the 3' hydroxyl group at the 3' end to prevent extension from the 3' end. Preferably, the blocking group remains covalently bound during subsequent processes associated with fixing the adapter-target-adapter polynucleotide to a solid surface and sequencing.

[0103] In some embodiments, dideoxynucleotides (ddNTPs) are incorporated into the 3' end of a polynucleotide to close the 3' end. The ddNTPs can be incorporated in any suitable manner. In some embodiments, the ddNTPs are incorporated by terminal deoxynucleotidyl transferase (TdT). TdT is capable of incorporating nucleotides into the 3' end of a single-stranded or double-stranded DNA without a template. In some embodiments, the ddNTPs are incorporated into the 3' end by TdT in the presence of a DNA polymerase such as, for example, Pol19, Pol812 or Pol963 polymerase. Non-limiting examples of other suitable polymerases are provided in U.S. Pat. Nos. 8,460,910, 8,852,910, 8,623,628, 9,273,352, 9,447,389, and U.S. Publication Nos. 2015 / 0376582, 2016 / 0032377, 2016 / 0090579, 2016 / 0115461, the entire contents of which are incorporated herein by reference.

[0104] In some embodiments, digoxigenin-labeled dideoxyuridine triphosphate is added to the 3' end using terminal transferase to block the 3' end. A kit for adding digoxigenin-labeled dideoxyuridine triphosphate to the 3' end of a polynucleotide is available from, for example, Sigma-Aldrich.

[0105] Any other suitable method may also be used to modify the 3' end of a polynucleotide.

[0106] During or after 3' blocking, many compounds and compositions may be obtained. For example, a polynucleotide having a nucleotide sequence of first adaptor-target-second adaptor may be obtained, wherein the 5' end of the polynucleotide is blocked, and the 3' end of the polynucleotide is blocked. Compositions or libraries comprising 5' modified and 3' blocked polynucleotides may be obtained. Pooled libraries of such polynucleotides and compositions comprising pooled libraries of such polynucleotides may be obtained.

[0107] By way of further example, a composition comprising such a polynucleotide and an enzyme and reagent for blocking the 3' end of the polynucleotide can be obtained. Similarly, a composition comprising a library of polynucleotides and an enzyme and reagent can be obtained. A composition comprising a library of such polynucleotides and an enzyme and reagent can be obtained. In some embodiments, the composition comprises ddNTPs. The composition can also comprise TdT. The composition can also comprise a DNA polymerase, such as, for example, Pol19, Pol812, or Pol963 polymerase.

[0108] A cleaning process such as that described above may be performed after closure.

[0109] Exonuclease treatment

[0110] After (or during) blocking, the resulting solution or composition comprising the resulting polynucleotide, whether or not first subjected to cleaning, may optionally be treated with an exonuclease. Preferably, the exonuclease treatment has 3' exonuclease activity to degrade any remaining polynucleotide not blocked by the 3'. Because the 5' end is tolerant to exonucleases, the exonuclease may have both 5' exonuclease activity and 3' exonuclease activity.

[0111] An exonuclease having "5' exonuclease activity" is an exonuclease that digests DNA in the 5' to 3' direction. An exonuclease having "3' exonuclease activity" is an exonuclease that digests DNA in the 3' to 5' direction.

[0112] An example of a suitable exonuclease having both 5' exonuclease activity and 3' exonuclease activity is Exonuclease V, which is the RecBCD complex from E. coli and available from, for example, New England Biolabs. Exonuclease V is also active on unnicked double-stranded DNA.

[0113] The exonuclease treatment can be performed on each library individually, or on the pooled libraries. After the exonuclease treatment, a clean-up step such as described above can be performed, and then the polynucleotides are immobilized on a solid surface for sequencing.

[0114] If the libraries have not yet been pooled, they can be pooled prior to immobilization on the sequencing surface.

[0115] Preparation of fixed samples for sequencing

[0116] The 5'modified and 3'closed library preparations collected can then be fixed on a solid surface to prepare for sequencing. Sequencing can be performed with an array of single molecules, or can be amplified before sequencing. Amplification can be implemented using one or more fixed primers. One or more fixed primers can be a lawn on a planar surface, a cluster on a planar surface, in a hole in a porous structure, on a pool of beads, etc. The pool of beads can be separated into emulsions, and in each "compartment (compartment)" of the emulsion, there is a single bead. At the concentration of only one template in each "compartment", only a single template is amplified on each bead.

[0117] The term "solid phase amplification" as used herein refers to any polynucleotide amplification reaction implemented on a solid support or in association with a solid support, so that all or a portion of the amplified products are fixed on the solid support when they are formed. In particular, the term includes solid phase polymerase chain reaction (solid phase PCR) and solid phase isothermal amplification, which is a reaction similar to standard solution phase amplification, except that one or both of the forward amplification primer and the reverse amplification primer are fixed on the solid support. Solid phase PCR covers systems, such as an emulsion in which one primer is anchored to a bead and another in a free solution, and a clone (colony) is formed in a solid phase gel matrix, in which one primer is anchored to a surface and one in a free solution.

[0118] Although the present disclosure includes a "solid phase" amplification method in which only one amplification primer is fixed (another primer is usually present in free solution), it is preferred to provide fixed forward primers and reverse primers to a solid support. In practice, because the amplification process requires excessive primers to maintain amplification, "more than one" identical forward primers and / or "more than one" identical reverse primers will be fixed on the solid support. Unless the context indicates otherwise, forward primers and reverse primers mentioned herein will be correspondingly interpreted as including "more than one" such primers.

[0119] As the skilled technical reader will appreciate, any given amplification reaction requires at least one type of forward primer and at least one type of reverse primer to be treated for template specific amplification. However, in certain embodiments, forward primer and reverse primer can comprise the template specific portion of the same sequence, and can have identical nucleotide sequence and structure (comprising any non-nucleotide modification). In other words, it is possible to implement solid phase amplification using only one type of primer, and such single primer method is included within the scope of the present invention. Other embodiments can use forward primer and reverse primer comprising the same template specific sequence but some of its other structural features are different. For example, one type of primer can comprise non-nucleotide modification not present in the primer of another type.

[0120] Throughout this disclosure, the terms "P5" and "P7" are used when referring to adapters and / or amplification primers. It will be understood that any suitable amplification primer can be used in the methods shown herein, and the use of P5 and P7 is only an exemplary embodiment. The use of amplification primers such as P5 and P7 on a flow cell is known in the art, as illustrated by the disclosures of WO 2007 / 010251, WO 2006 / 064199, WO 2005 / 065814, WO 2015 / 106941, WO 1998 / 044151, and WO 2000 / 018957, each of which is incorporated by reference in its entirety. For example, any suitable forward amplification primer, whether fixed or in solution, can be used in the methods shown herein for hybridization with complementary sequences and amplification sequences. Similarly, any suitable reverse amplification primer, whether fixed or in solution, can be used in the methods shown herein for hybridization with complementary sequences and amplification sequences. Those skilled in the art will understand how to design and use primer sequences suitable for capturing and amplifying nucleic acids as presented herein.

[0121] Primers for solid phase amplification are preferably fixed by covalent attachment to a solid support single point at or near the 5' end of the primer, so that the template-specific portion of the primer is freely annealed to its associated template and the 3' hydroxyl group is free for primer extension. Any suitable covalent attachment means known in the art can be used for this purpose. The attachment chemistry selected will depend on the properties of the solid support, as well as any derivatization or functionalization applied to it. The primer itself can include a part that can be a non-nucleotide chemical modification to promote attachment. In some embodiments, the primer includes a sulfur-containing nucleophile at the 5' end, such as thiophosphate (phosphorothioate) or thiophosphate (thiophosphate). The surface of the solid support can include or be modified to include a part that includes a sulfur-containing nucleophile that can be attached. For example, a sulfur-containing nucleophile can be combined with a bromoacetamide group. In some embodiments, the polyacrylamide hydrogel of the solid support includes a bromoacetamide group for combining a sulfur-containing nucleophile. A more specific means of attaching primers and template to a solid support is by 5' phosphorothioate attachment to a hydrogel comprising polymerized acrylamide and N-(5-bromoacetamidopentyl)acrylamide (BRAPA), as fully described in WO 2005 / 065814.

[0122] Solid supports comprising inert substrates or matrix (e.g., slides, polymer beads, etc.) can be, for example, "functionalized" by applying an intermediate material layer or coating comprising a reactive group, which allows covalent attachment to biomolecules such as polynucleotides. Examples of such supports include, but are not limited to, polyacrylamide hydrogels supported on inert substrates such as glass. In such embodiments, biomolecules (e.g., polynucleotides) can be directly covalently attached to intermediate materials (e.g., hydrogels), but intermediate materials themselves can be non-covalently attached to substrates or matrix (e.g., glass substrates). The term "covalently attached to a solid support" will be understood to include this type of arrangement accordingly.

[0123] The library samples collected can be amplified on a solid surface comprising forward and reverse amplification primers. In some embodiments, the library collected by polynucleotide is used for the array of clustering of polynucleotide clones prepared by solid phase amplification and more particularly by solid phase isothermal amplification, similar to those described in U.S. Patent Publication No. 2005 / 0100900, U.S. Patent No. 7,115,400, WO 00 / 18957 and WO 98 / 44151. The terms "cluster" and "clone" are interchangeably used herein to refer to discrete sites comprising more than one identical fixed nucleic acid chain and more than one identical fixed complementary nucleic acid chain on a solid support. The term "clustered array" refers to an array formed by such a cluster or clone. In this article, the term "array" should not be construed as requiring the orderly arrangement of clusters.

[0124] The terms solid phase or surface are used to mean a planar array (in which primers are attached to a flat surface, e.g., a glass, silica, or plastic microscope slide) or a similar flow cell device; beads, in which one or two primers are attached to the beads and the beads are amplified; an array of beads on a surface (after the beads have been amplified), etc.

[0125] The terms "solid surface," "solid support," and other grammatical equivalents herein refer to any material that is suitable or can be modified to be suitable for attachment of a template polynucleotide. As will be appreciated by those skilled in the art, the number of possible substrates is extremely large. Possible substrates include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylic, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethane, The solid supports and solid surfaces particularly useful for some embodiments are located within a flow cell device. Exemplary flow cells are described in more detail below.

[0126] In some embodiments, the solid support comprises a patterned surface." patterned surface " refers to the arrangement of different regions in the layer exposed by the solid support or on the exposed layer. For example, one or more regions can be the feature in which one or more amplification primers are present. The feature can be separated by the gap region in which there is no amplification primer. In some embodiments, the pattern can be the feature of the xy format in rows and columns. In some embodiments, the pattern can be the repeated arrangement of the feature and / or gap region. In some embodiments, the pattern can be the random arrangement of the feature and / or gap region. The exemplary patterned surface that can be used for the method and composition set forth herein is described in U.S. Patent No. 8,778,848, No. 8,778,849, No. 9,079,148 and U.S. Publication No. 2014 / 0243224.

[0127] In some embodiments, the solid support includes an array of holes or depressions in the surface. As is generally known in the art, this can be manufactured using a variety of techniques including, but not limited to, photolithography, stamping techniques, molding techniques, and microetching techniques. As will be understood by those skilled in the art, the techniques used will depend on the composition and shape of the array substrate.

[0128] The features in the patterned surface can be holes (e.g., micropores or nanopores) in an array of holes on a glass, silicon, plastic or other suitable solid support with a patterned, covalently attached gel, such as poly (N- (5-azidoacetamidopentyl) acrylamide-co-acrylamide) (PAZAM, see, e.g., U.S. Publication Nos. 2013 / 184796, WO 2016 / 066586, and WO 2015 / 002813). The process produces a gel pad for sequencing that can be stable over a large number of cycles of sequencing runs. The covalent attachment of the polymer to the hole helps maintain the gel in the structured features throughout the life of the structured substrate during a variety of uses. However, in many embodiments, the gel does not have to be covalently attached to the hole. For example, under some conditions, a silane-free acrylamide (SFA, see, e.g., U.S. Patent No. 8,563,477) that is not covalently attached to any portion of the structured substrate can be used as the gel material.

[0129] In certain embodiments, the solid support material can be patterned with holes (e.g., micropores or nanopores), the patterned support can be coated with a gel material (e.g., PAZAM, SFA, or a chemically modified variant thereof, such as an azidized form of SFA (azido-SFA)), and the gel-coated support can be polished, for example, by chemical or mechanical polishing, so that the gel is retained in the holes, but substantially all of the gel in the interstitial regions between the holes on the surface of the structured substrate is removed or substantially all of the gel is inactivated. Primer nucleic acids can be attached to the gel material. Then a solution of target nucleic acids (e.g., a fragmented human genome) can be contacted with the polished substrate so that individual target nucleic acids will inoculate individual holes by interacting with primers attached to the gel material; however, due to the absence or inactivity of the gel material, the target nucleic acid will not occupy the interstitial region. The amplification of the target nucleic acid will be limited to the holes because the absence or inactivity of the gel in the interstitial region prevents the outward migration of the growing nucleic acid clones. The process is conveniently manufacturable, can be scaled up, and conventional micro or nano manufacturing methods can be used. As used herein, the term "flow cell" refers to a chamber comprising a solid surface across which one or more fluid reagents can flow. Examples of flow cells and associated fluid systems and detection platforms that can be readily used in the methods of the present disclosure are described below: e.g., Bentley et al., Nature 456:53-59 (2008); WO 04 / 018497; US 7,057,026; WO 91 / 06678; WO 07 / 123744; US 7,329,492; US 7,211,414; US 7,315,019; US 7,405,281 and US 2008 / 0108082.

[0130] In some embodiments, the solid support or its surface is non-planar, such as the inner or outer surface of a tube or container. In some embodiments, the solid support comprises microspheres or beads. As used herein, "microspheres" or "beads" or "particles" or grammatical equivalents refer to small discrete particles. Suitable bead compositions include, but are not limited to, plastics, ceramics, glass, polystyrene, methylstyrene, acrylic polymers, paramagnetic materials, thoria sols, carbon graphite, titanium dioxide, latex, or cross-linked dextran such as Sepharose, cellulose, nylon, cross-linked micelles and And any other material outlined herein for solid supports may be used. The "Microsphere Detection Guide" from Bangs Laboratories, Fishers Ind. is a useful guide. In certain embodiments, the microspheres are magnetic microspheres or beads.

[0131] The beads need not be spherical; irregular particles may be used. Alternatively or additionally, the beads may be porous. Bead sizes range from nanometers, i.e., 100 nm, to millimeters, i.e., 1 mm, with beads from about 0.2 microns to about 200 microns being preferred, and beads from about 0.5 microns to about 5 microns being particularly preferred, although in some embodiments, smaller or larger beads may be used.

[0132] Clustered arrays can be prepared using a thermal cycling process as described in WO / 9844151 or a process wherein the temperature is maintained constant and a change in reagents is used to carry out a cycle of extension and denaturation. Such isothermal amplification methods are described in patent applications No. WO / 0246456 and No. US 2008 / 0009420. This is particularly preferred due to the requirement for lower temperatures in the isothermal process.

[0133] It will be appreciated that any amplification method described herein or generally known in the art can be used with universal primers or target-specific primers to amplify fixed DNA fragments. Suitable methods for amplification include but are not limited to polymerase chain reaction (PCR), strand displacement amplification (SDA), transcription-mediated amplification (TMA) and amplification based on nucleic acid sequence (NASBA), as described in U.S. Patent No. 8,003,354, which is incorporated herein by reference in its entirety. The above amplification method can be used to amplify one or more nucleic acids of interest. For example, PCR includes multiple PCR, SDA, TMA, NASBA, etc. can be used to amplify fixed DNA fragments. In some embodiments, primers specifically for polynucleic acids of interest are included in the amplification reaction.

[0134] Other suitable methods for amplifying polynucleotides can include oligonucleotide extension and ligation, rolling circle amplification (RCA) (Lizardi et al., Nat. Genet. 19: 225-232 (1998)) and oligonucleotide ligation assay (OLA) (see generally U.S. Patents Nos. 7,582,420, 5,185,243, 5,679,524 and 5,573,907; EP 0 320 308 B1; EP 0 336 731 B1; EP 0 439182 B1; WO 90 / 01069; WO 89 / 12696; and WO 89 / 09835) techniques. It will be appreciated that these amplification methods can be designed to amplify fixed DNA fragments. For example, in some embodiments, the amplification method can include ligation probe amplification or oligonucleotide ligation assay (OLA) reactions, which include primers specifically for the nucleic acid of interest. In some embodiments, the amplification method may include a primer extension-ligation reaction including primers specific for the nucleic acid of interest. As a non-limiting example of primer extension and ligation primers that can be specifically designed to amplify the nucleic acid of interest, the amplification may include primers for GoldenGate assay (Illumina, Inc., San Diego, CA), as exemplified by U.S. Patents Nos. 7,582,420 and 7,611,869.

[0135] Exemplary isothermal amplification methods that can be used in the methods of the present disclosure include, but are not limited to, multiple displacement amplification (MDA) as exemplified by, e.g., Dean et al. Proc. Natl. Acad. Sci. USA 99:5261-66 (2002), or isothermal strand displacement nucleic acid amplification as exemplified by, e.g., U.S. Pat. No. 6,214,587. Other non-PCR-based methods that can be used in the present disclosure include, for example, Walker et al., Molecular Methods for Virus Detection, Academic Press, Inc., 1995; U.S. Pat. Nos. 5,455,166 and 5,130,238, and Walker et al., Nucl. Acids Res. 20:1691-96 (1992) described in strand displacement amplification (SDA), or hyper-branched strand displacement amplification described in, for example, Lage et al., Genome Res. 13:294-307 (2003). For random primer amplification of genomic DNA, isothermal amplification methods can be used with strand displacement Phi 29 polymerase or Bst DNA polymerase large fragment, 5'->3'exo-. The use of these polymerases takes advantage of their high processivity and strand displacement activity. High processivity allows the polymerase to produce fragments of 10kb-20kb in length. As set forth above, smaller fragments can be generated under isothermal conditions using a polymerase with low processivity and strand displacement activity, such as Klenow polymerase.Additional description of amplification reactions, conditions, and components are set forth in detail in the disclosure of U.S. Pat. No. 7,670,810, which is incorporated herein by reference in its entirety.

[0136] Another nucleic acid amplification method useful in the present disclosure is Tagged PCR, which uses a population of two-domain primers with a constant 5' region followed by a random 3' region, as described, for example, in Grothues et al. Nucleic Acids Res. 21(5): 1321-2 (1993). The first multiple rounds of amplification are performed to allow a large number of starts based on hybridization from the randomly synthesized 3' region alone on heat-denatured DNA. Due to the nature of the 3' region, the start site is expected to be random across the genome. Thereafter, unbound primers can be removed and additional replication can occur using primers complementary to the constant 5' region.

[0137] In some embodiments, isothermal amplification can be carried out using the kinetic exclusion amplification (KEA) also referred to as exclusion amplification (ExAmp). The nucleic acid library of the present disclosure can be prepared using a method comprising reacting an amplification reagent to produce a step more than one amplification site, each of which comprises a substantially clonal population of the amplicon from the independent target nucleic acid inoculated in the site. In some embodiments, the amplification reaction proceeds to produce a sufficient number of amplicon to fill the capacity of the corresponding amplification site. Filling the site inoculated in this way to the capacity suppresses the landing and amplification of the target nucleic acid at the site, thereby producing a clonal population of the amplicon at the site. In some embodiments, even if the amplification site is not filled to the capacity before the second target nucleic acid arrives at the site, it is also possible to realize apparent clonality. Under some conditions, the amplification of the first target nucleic acid can proceed to a sufficient number of copies to be produced to effectively outperform or overwhelm the point produced from the copy of the second target nucleic acid transported to the site. For example, in an embodiment using a bridge amplification process for circular features less than 500 nm in diameter, it has been determined that after 14 cycles of exponential amplification of a first target nucleic acid, contamination from a second target nucleic acid at the same site will produce insufficient numbers of contaminating amplicons to adversely affect sequencing-by-synthesis analysis on an Illumina sequencing platform.

[0138] As demonstrated by the examples above, in a particular embodiment, the amplification sites in the array can be but need not be completely cloned. Rather, for some applications, the individual amplification sites can be mainly populated with the amplicon from the first target nucleic acid, and can also have low-level contamination amplicon from the second target nucleic acid. As long as the contamination level does not have an unacceptable impact on the subsequent use of the array, the array can have one or more amplification sites with low-level contamination amplicon. For example, when the array will be used in a detection application, an acceptable contamination level will be a level that will not affect the signal-to-noise ratio or resolution of the detection technology in an unacceptable manner. Therefore, apparent clonality will generally be related to the specific use or application of the array made by the method set forth herein. Exemplary contamination levels that can be accepted at the individual amplification sites for specific applications include but are not limited to at most 0.1%, 0.5%, 1%, 5%, 10% or 25% contamination amplicon. The array can include one or more amplification sites with the contamination amplicon of these exemplary levels. For example, up to 5%, 10%, 25%, 50%, 75% or even 100% of the amplification sites in the array can have some contamination amplicon. It will be appreciated that at least 50%, 75%, 80%, 85%, 90%, 95%, or 99% or more of the sites in an array or other collection of sites may be clonal or apparent clonal.

[0139] In some embodiments, kinetic exclusion can occur in a process when a sufficiently fast rate occurs to effectively exclude another event or process. Taking the preparation of nucleic acid array as an example, the site of the array is randomly inoculated with the target nucleic acid from the solution, and a copy of the target nucleic acid is produced in the amplification process to fill each inoculated site to capacity. According to the kinetic exclusion method of the present disclosure, inoculation and amplification process can be carried out simultaneously under the condition that the amplification rate exceeds the inoculation rate. Therefore, the relatively fast rate of copying at the site inoculated by the first target nucleic acid will effectively exclude the second nucleic acid inoculation site for amplification. Kinetic exclusion amplification method can be carried out as described in detail in No. 2013 / 0338042 of the U.S. Publication, which is incorporated herein by reference in its entirety.

[0140] Kinetics excludes the relatively fast rate of the subsequent copy of the target nucleic acid (or the first copy of the target nucleic acid) that can be utilized to amplify the initial relatively slow rate (for example, the slow rate of preparing the first copy of the target nucleic acid) contrast preparation.In the example of the previous paragraph, the occurrence of kinetics excludes the relatively fast rate of the subsequent copy of the target nucleic acid (or the first copy of the target nucleic acid) due to the relatively slow rate (for example, relatively slow diffusion or transport) of the target nucleic acid inoculation contrast amplification occurs to fill the site with a copy of the nucleic acid seed.In another exemplary embodiment, the occurrence of kinetics excludes can be due to the delay (for example, delayed or slow activation) of the formation of the first copy of the target nucleic acid inoculated site contrast preparation to copy to fill the site.In this example, a single site may have been inoculated with several different target nucleic acids (for example, several target nucleic acids can be present in each site before amplification).However, for any given target nucleic acid, the first copy formation can be randomly activated, so that the average rate of the first copy formation is relatively slow compared with the rate of producing the subsequent copy.In this case, although a single site may have been inoculated with several different target nucleic acids, kinetics excludes the one that will only allow those target nucleic acids to be amplified. More specifically, after a first target nucleic acid has been activated for amplification, the site will quickly be filled to capacity with copies of the first target nucleic acid, thereby preventing copies of the second target nucleic acid from being made at the site.

[0141] Amplification reagents can include additional components that promote amplicon formation and increase the rate of amplicon formation in some cases. An example is a recombinase. Recombinases can promote amplicon formation by allowing repeated invasion / extension. More specifically, recombinases can promote the invasion of target nucleic acids by polymerases, and use target nucleic acids as templates for amplicon formation by polymerase extension primers. This process can be repeated as a chain reaction, wherein the amplicon produced from each round of invasion / extension is used as a template in a subsequent round. Because denaturation cycles (such as by heating or chemical denaturation) are not required, this method can occur faster than standard PCR. Therefore, the amplification promoted by recombinases can be implemented isothermally. It is generally desirable to include ATP or other nucleotides (or in some cases, its non-hydrolyzable analogs) in the amplification reagents promoted by recombinases to promote amplification. A mixture of recombinase and single-stranded binding (SSB) protein is particularly useful because SSB can further promote amplification. Exemplary preparations for amplification promoted by recombinases include those sold commercially by TwistDx (Cambridge, UK) with TwistAmp test kits. Useful components and reaction conditions for recombinase-facilitated amplification reagents are described in US Pat. Nos. 5,223,414 and 7,399,590, the contents of which are incorporated herein by reference.

[0142] Another example of a component that can be included in the amplification reagent to promote amplicon formation and increase the speed of amplicon formation in some cases is a helicase. Helicase can promote amplicon formation by a chain reaction that allows amplicon formation. Because denaturation cycles (e.g., by heating or chemical denaturation) are not required, the process can occur faster than standard PCR. Therefore, the amplification promoted by helicase can be implemented isothermally. The mixture of helicase and single-stranded binding (SSB) protein is particularly useful because SSB can further promote amplification. Exemplary formulations for the amplification promoted by helicase include those sold commercially from Biohelix (Beverly, MA) with IsoAmp test kits. In addition, examples of useful formulations including helicase proteins are described in US 7,399,590 and US 7,829,284, each of which is incorporated herein by reference.

[0143] Yet another example of a component that can be included in an amplification reagent to promote, and in some cases increase the rate of, amplicon formation is an origin binding protein.

[0144] Uses in sequencing / sequencing methods

[0145] The fixed polynucleotides from the pooled libraries can be sequenced in any suitable manner. Preferably, sequencing is performed by sequencing by synthesis, wherein nucleotides are continuously added to the free 3' hydroxyl group of the sequencing primer using the fixed polynucleotide as a template, resulting in the synthesis of the polynucleotide chain in the 5' to 3' direction. Preferably, the properties of the added nucleotides are determined after each nucleotide addition. Sequencing techniques using sequencing by ligation (wherein not every connected base is sequenced), and techniques such as massively parallel signature sequencing (MPSS) (wherein bases are removed from chains on the surface rather than added to chains on the surface), and techniques using pyrophosphate release detection (pyrophosphate sequencing) are also within the scope of the present disclosure. Such pyrophosphate sequencing-based techniques are particularly suitable for array sequencing of beads, where beads have been amplified in emulsions so that a single template from a library molecule is amplified on each bead.

[0146] A starting point for the sequencing reaction can be provided by annealing a sequencing primer to the product of a solid phase amplification reaction. In this regard, one or both adapters added during template library formation can include a nucleotide sequence that allows a sequencing primer to anneal to a fixed polynucleotide such as an adapter-target-adapter polynucleotide.

[0147] The index tag sequence and target sequence can be determined in a single read from a single sequencing primer, or in multiple reads from more than one sequencing primer. In the case of two reads from two sequencing primers, the "index tag read" and the "target read" can be performed in either order, with a suitable denaturation step after the first sequencing read is completed to remove the annealed primer. As is generally known in the art, suitable denaturation steps can include formamide, hydroxide or heat treatment.

[0148] The product of a solid phase amplification reaction in which both a forward amplification primer and a reverse amplification primer are covalently fixed on a solid surface can be a so-called "bridged" structure formed by annealing of a fixed polynucleotide chain and a fixed complementary chain, both chains being attached to a solid support at the 5' end. An array comprising such a bridged structure cannot provide an effective template for nucleic acid sequencing because, under standard conditions for hybridization, hybridization of a conventional sequencing primer to one of the fixed chains is not supported compared to the fixed complementary chain to which the chain is annealed. Examples of bridge amplification or cluster amplification are described in, for example, U.S. Patents Nos. 7,985,565 and 7,115,400.

[0149] In order to provide a template that is more suitable for nucleic acid sequencing, it is preferred to substantially remove all of one of the fixed chains in the "bridged" structure, or remove or replace at least a portion of one of the fixed chains in the "bridged" structure, to produce a template that is at least partially single-stranded. The single-stranded portion of the template will therefore be used for hybridization with a sequencing primer. The process of removing all or a portion of a fixed chain in a "bridged" double-stranded nucleic acid structure can be referred to as "linearization" in this article, and is described in further detail in WO 2007 / 010251, WO 2006 / 064199, WO 2005 / 065814, WO 2015 / 106941, WO1998 / 044151 and WO 2000 / 018957.

[0150] The bridged template structure can be linearized by cleaving one or both strands with a restriction endonuclease or by cleaving one strand with a nicking endonuclease. Other methods of cleavage can be used as an alternative to restriction enzymes or nicking enzymes, including, among others, chemical cleavage (e.g., cleavage of diol linkages with periodate), cleavage by cleavage with an endonuclease (e.g., "USER", Cat# M5505S, provided by NEB) or by exposure to heat or alkali to cleave abasic sites, cleavage of ribonucleotides incorporated into amplification products that originally contained deoxyribonucleotides, photochemical cleavage, or cleavage of peptide linkers.

[0151] It will be appreciated that if the solid phase amplification reaction is performed with only one covalently immobilized primer and another primer in free solution, a linearization step may not be essential.

[0152] After the cleavage step, regardless of the method for cracking, the product of the cleavage reaction can undergo denaturation conditions to remove one or more parts of the chain of one or more cracks that are not attached to the solid support. Suitable denaturation conditions, such as sodium hydroxide solution, formamide solution or heating, for reference standard molecular biology protocols (Sambrook et al., 2001, Molecular Cloning, A Laboratory Manual, the 3rd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor Laboratory Press, NY; Current Protocols, Ausubel et al. write) skilled readers will be obvious. Denaturation causes the generation of partially or substantially single-stranded sequencing templates. Then the sequencing reaction can be initiated by hybridization of the single-stranded portion of the sequencing primer with the template.

[0153] Thus, in some embodiments, the sequencing reaction includes hybridizing a sequencing primer to a single-stranded region of a linearized amplification product, successively incorporating one or more nucleotides into a polynucleotide chain complementary to the region of the amplified template chain to be sequenced, identifying the bases present in the one or more incorporated nucleotides, and thereby determining the sequence of the region of the template chain.

[0154] A preferred sequencing method that can be used relies on the use of modified nucleotides with removable 3' closures, such as described in WO 2004 / 018497 and U.S. Patent No. 7,057,026. After the modified nucleotides have been incorporated into the growing polynucleotide chain complementary to the region of the template being sequenced, because there is no free 3'-OH group can be used to guide other sequence extensions, and therefore the polymerase cannot add other nucleotides. After the properties of the bases incorporated into the growing chain have been determined, the 3' closure can be removed to allow the addition of the next continuous nucleotide. By sorting the products obtained using these modified nucleotides, it is possible to infer the DNA sequence of the DNA template. If each modified nucleotide has different markers attached to it, it is known that the marker corresponds to a specific base to help distinguish the bases added during each incorporation step, then such a reaction can be completed in a single experiment. Alternatively, an independent reaction containing each modified nucleotide alone can be implemented.

[0155] The modified nucleotide can carry a label to facilitate its detection. For example, a fluorescent label can be used to detect the modified nucleotide. Therefore, each nucleotide type can carry different fluorescent labels, such as described in WO 2007 / 135368. However, detectable labels are not necessarily fluorescent labels. Any label allowing detection of the incorporated nucleotide can be used.

[0156] A method for detecting fluorescently labeled nucleotides comprises using a laser with a wavelength specific to the nucleotides of the label, or using other suitable sources of illumination. The fluorescence from the markers on the nucleotides can be detected by a CCD camera or other suitable detection means. Suitable instruments for recording images of clustered arrays are described in WO 2007 / 123744.

[0157] Of course, any other suitable sequencing method can be used. Preferably, the sequencing method relies on the continuous incorporation of nucleotides into the polynucleotide chain. Suitable optional techniques include, for example, pyrophosphate sequencing, FISSEQ (fluorescence in situ sequencing), MPSS, and sequencing by a method based on connection, such as described in U.S. Patent No. 6,306,597.

[0158] The nucleic acid sample can be further analyzed to obtain a second read from the opposite end of the fragment. Methods for sequencing the two ends of the cluster are described in WO 2007 / 010252 and WO 2008 / 041002. In one example, a series of steps can be performed as follows: generate clusters, linearize, hybridize the first sequencing primer and obtain the first sequencing read. The first sequencing primer can be removed, hybridize the second primer and sequence the index tag. The polynucleotide chain can then be "inverted" on the surface by synthesizing complementary copies from the remaining fixed primers used in cluster amplification. This process of chain resynthesis regenerates double-stranded clusters. The original template chain can be removed to linearize the resynthesized chain, which can then anneal to the sequencing primer and sequence in the third sequencing run.

[0159] Where strand resynthesis is used, the two strands may be fixed to the surface in a manner that allows for subsequent release of a portion of the fixed strand. This may be achieved by a number of mechanisms as described in WO 2007 / 010251. For example, a primer may comprise uracil nucleotides, which means that the strands may be cleaved at uracil bases using uracil glycosylase (UDG) to remove nucleoside bases and endonuclease VIII to excise abasic nucleotides. This enzyme combination is available from New England Biolabs (Cat# M5505) as USER TMEnzyme available. The second primer can contain 8-oxoguanine nucleotides, which can then be cleaved by the enzyme FPG (NEB Cat#M0240). This design of primers provides control over which primer is cleaved at which point in the process, and also at which positions in the cluster that cleavage occurs. Primers can also be chemically modified, such as with disulfide or diol modifications that allow chemical cleavage at specific positions.

[0160] Reference now Figure 1 , which is a schematic diagram illustrating an embodiment of a process for generating 5' modified and 3' blocked template polynucleotides to be immobilized on a solid surface for sequencing. Figure 1 In A, a double-stranded target polynucleotide fragment is shown. The initial part of the adapter can be connected by ligation (see Figure 1 B) or labeled fragments and attached to the ends of the target. The portion of the adaptor (ab) includes a double-stranded portion that is attached to the double-stranded target and a single-stranded portion that extends away from the 5' end and 3' end of the target. The 5' modified primer (B') is configured to hybridize with the single-stranded portion (b) of the adaptor near the 3' end ( Figure 1 C). A polymerase can be used to extend primer B' using the portions of the adaptor and the target as templates to generate the complementary sequence of the portions of the adaptor (a') and the complementary sequence of the target ( Figure 1 D, for convenience and clarity, from Figure 1 The 5' modified primer (A) is configured to hybridize near the 3' end to the single stranded portion (a') of the complementary sequence of the adaptor portion ( Figure 1 E). A polymerase can be used to extend primer A using portions of the complementary sequences of the adaptor and target as templates to produce portions of the adaptor (b) and target (c). Figure 1 F, for convenience and clarity, comes from Figure 1 E's chain is removed).

[0161] If the added adaptor portion contains a library-specific index tag sequence at a position between the sequence for hybridization of primers (A, B') and the target (when the adaptor portion is attached to the target) by, for example, ligation or labeling, amplification with primers (A, B') can be performed on pooled target fragments from different libraries ( Figure 1 CF), provided that each fragment from each library includes a portion of the adaptor with a library-specific index tag sequence at a similar position and each portion of the adaptor from each library has a sequence (or complementary sequence) to which the primers (A, B') can hybridize. Otherwise, each library should be amplified separately.

[0162] The resulting 5' protected template (amplified adapter-target-amplified adapter) can be 3' blocked to produce a 5' and 3' protected template polynucleotide ( Figure 1 G) for immobilization on a solid surface for sequencing. 3' blocking may affect any polynucleotides present in solution with the 5' protected template, including any other amplified fragments or remaining polynucleotides (not shown). Therefore, if the adapter portion (ab) is amplified by primers (A, B'), the amplified adapter not attached to the template (not shown) should also be 3' blocked.

[0163] An exonuclease treatment may optionally be applied to the resulting mixture.Before immobilizing the template polynucleotide on the solid surface, the remaining unblocked or unprotected polynucleotide may be degraded.

[0164] Reference now Figure 2 Schematic diagram of an adapter (amplified adapter) 100 that can be used or obtained during amplification of a library prepared for sequencing. The depicted adapter 100 includes a double-stranded region 110 and a non-complementary single-stranded region 120. The 5' end is modified (indicated by "*") to prevent degradation by exonucleases, and the 3' end is blocked (indicated by "X"). One strand of the depicted adapter 100 includes a universal extension primer sequence 130, an index tag sequence 132, and a sequencing primer sequence 134. The other strand of the depicted adapter 100 includes a universal extension primer sequence 140, an index tag sequence 142, and a sequencing primer sequence 144.

[0165] Universal extension primer sequences 130, 140 can hybridize with extension primer oligonucleotides attached to a solid surface for amplification or sequencing purposes (if adaptor 100 is attached to a target polynucleotide). Universal extension primer sequence 140 or a portion thereof can also hybridize with a sequencing primer to sequence index tag sequence 142. Optionally, the strand can include additional sequencing primer sequences (not shown).

[0166] Sequencing primer sequence 134 may hybridize to a sequencing primer to allow sequencing of index tag sequence 132. Index tag sequence 142 and index tag sequence 132 may be the same or different.

[0167] Sequencing primer sequence 144 can hybridize to a sequencing primer to allow sequencing of the target polynucleotide sequence (if attached to adaptor 100).

[0168] If the adaptors are attached to the target in a multi-step process as described above, the sequencing primer sequences 134, 144 can hybridize to, for example, PCR primers.

[0169] It will be appreciated that suitable adaptors for use in the various embodiments described herein may have more Figure 2 The described sequence features may have more or fewer sequence features or other sequence features in addition to those sequence features.

[0170] Reference now Figure 3 , shows a schematic diagram of a template polynucleotide 200 of a library having an adaptor 100-template 210-adaptor 101 sequence. Template 210 is double-stranded and attached to the double-stranded portions of the first adaptor 100 and the second adaptor 101. For example, as described above, the 3' end of the template polynucleotide 200 is blocked and the 5' end is modified.

[0171] Reference now Figure 4 , schematic illustrations of a process for amplifying a template polynucleotide 200 from a library cluster to a solid surface 300 in preparation for sequencing are shown. In the first figure, a template polynucleotide 200 having a modified 5' end and a blocked 3' end is hybridized to a first extension primer 310 attached to a solid surface 300. For example, Figure 2 The universal extension primer sequence 140 portion of the adapter depicted in can hybridize to the first extension primer 310.

[0172] The first extension primer 310 contains a free 3' end, and thus nucleotides can be added to the 3' end in the presence of a suitable polymerase using the template polynucleotide 200 as a template to produce a copy template strand 201 attached to the solid surface 300 (see the second figure). The template strand 200 can be removed, and the copy strand 201 can be hybridized with the second extension primer 320 attached to the solid surface 300 (see the third figure). For example, Figure 2 The universal extension primer sequence 130 portion of the adaptor depicted in can hybridize to the second extension primer 320.

[0173] The second extension primer 320 contains a free 3' end, and thus nucleotides can be added to the 3' end in the presence of a suitable polymerase using the copy template polynucleotide 201 as a template to produce an amplified template strand 202 (see fourth figure) attached to the solid surface 300. Additional rounds of amplification can be performed to produce clusters of copy template strands 201 and amplified template strands 202.

[0174] For illustration purposes, Figure 4 The fifth figure of FIG. 1 depicts the copied template strand 201 and the amplified template strand 202 in linear form.

[0175] Reference now Figure 5 , shows a schematic diagram illustrating how blocking the 3' end (to prevent extension from the blocked 3' end) can reduce index jumping. Figure 5 The first two pictures and Figure 4 The first two figures are the same. Figure 5As shown in the third figure of , the remaining unincorporated (not attached to the target polynucleotide) adapter chain 104 can hybridize with the adapter portion of the copy template chain 201 (for example, hybridization can occur between the double-stranded region of the adapter and the adapter portion of the template polynucleotide). The adapter chain 104 can come from a library different from the library from which the copy template chain 201 originates. Therefore, the adapter 104 can have an index tag sequence that is different from the index tag sequence associated with the copy template chain 201. Because the 3' end of the adapter is blocked (indicated by an "X"), the adapter 104 cannot be used as an effective primer for extending and copying the copy template chain 201. However, if extension is allowed (and the 3' end of the unincorporated adapter 104 is not blocked), a copy will be produced in which an incorrect index tag (the index tag of the adapter 104 from the second library) will be associated with a target polynucleotide from another library (the target polynucleotide of the template polynucleotide 201 from the first library). In a subsequent round of amplification, incorrectly indexed polynucleotides may attach to surface 300 .

[0176] Reference now Figure 6 , shows a schematic diagram illustrating how exonuclease treatment to remove unblocked and unincorporated adapters or adapter strands can reduce index jumping. Figure 6 The first two pictures and Figure 4 The first two figures are the same. Figure 6 , which may result from amplification (e.g., as described with respect to Figure 1 BF), at the 3' blocking step (e.g., as described for Figure 1 G) can hybridize with the adapter portion of the copy template chain 201 (for example, hybridization can occur between the double-stranded region of the adapter and the adapter portion of the template polynucleotide). The adapter chain 104 can come from a library different from the library from which the copy template chain 201 originates. Therefore, the adapter chain 104 can have an index tag sequence that is different from the index tag sequence associated with the copy template chain 201. The adapter chain 104 can be used as an effective primer for extending and copying the copy template chain 201. An amplified chain will be produced in which an incorrect index tag (the index tag of the adapter chain 104 from the second library) will be associated with a target polynucleotide from another library (the target polynucleotide of the template polynucleotide 201 from the first library). In a subsequent round of amplification, the incorrectly indexed polynucleotide can be attached to the surface 300. However, and as Figure 6 As illustrated in the lower right figure of , if unblocked adapters are available or adapter strands are digested by exonuclease treatment, the adapter strands are not available as extension primers and index jumping is reduced.

[0177] Reference now Fig. 7A and7B , illustrating the nature of the index jumping phenomenon. Fig. 7A It shows how reads from a given sample can be incorrectly demultiplexed and mixed with different samples after demultiplexing. Figure 7B We demonstrate index jumping in a dual-index system, where the index jumps lead to unexpected combinations of index label sequences.

[0178] Reference now Fig. 8A and 8B , illustrates a general method for measuring the index jump rate in a given system. Fig. 8A An exemplary layout of a dual adaptor plate is shown, where each individual well of a 96-well plate contains a unique pair of index tag sequences (12 different P7 indexes combined with 8 different P5 indexes). Figure 8B An experimental setup designed to measure index jump rates is shown, where 8 unique dual-index tag combinations were used (i.e. no P5 index was expected to be paired with more than one P7 index, and vice versa). Unexpected combinations of index tags (e.g. D505-D703) were then easily identified as instances of index jumps.

[0179] Reference now Fig. 9A and 9B , illustrating the effect of unligated adapters on index hopping rate. Fig. 9A A 6-fold increase in the index jump associated with 50% incorporation of free adaptor is shown. Fig. 9B The effect of free forked adaptors on index jump rate is shown to be approximately linear over the range tested. The inventors also observed that free single-stranded P7 adaptors had a more pronounced effect on index jump rate than free single-stranded P5 adaptors (data not shown). Example

[0180] Example 1: Example protocol for 3' blocking of 5' protected indexed libraries

[0181] This protocol explains how to perform 3' blocking on 5' protected DNA libraries to reduce index hopping. The method is designed to be performed on a pool of DNA libraries and then analyzed using Illumina 4000 and similar sequencing platforms (using patterned flow cells and ExAmp-based clustering) (e.g., X and ) for the denaturation step and subsequent cluster generation.

[0182] Index jumping has been observed to occur when incorrect index sequences are assigned to insert sequences, resulting in sample misassignment. Such treatment of the DNA sample pool prior to running on the 4000 should reduce the level of index jumping to a level that cannot be consistently predicted at this stage.

[0183] The processing workflow can be considered to include four steps: (i) generating DNA sample pools; (ii) performing processing, (iii) cleaning up samples and quantifying; and (iv) clustering and sequencing the sample pools.

[0184] Consumables / Equipment : Consumables and equipment can be provided by the sequencing user or manufacturer. User-supplied consumables can include a DNA library sample pool—30 μl at a concentration to be used for denaturation during clustering. The user can also provide freshly prepared 80% ethanol (EtOH).

[0185] Table 1 below describes some of the consumables and equipment that may be used.

[0186] Table 1: Consumables and Equipment

[0187]

[0188] Sequencing manufacturers may provide BMX (blocking mix), EMX (exonuclease mix), RSB (resuspension buffer), and SPB (sample purification beads).

[0189] EMX can include exonuclease buffer (67 mM glycine-KOH, 2.5 mM MgCl2, 50 μg / ml BSA) and lambda exonuclease (New England Biolabs, Cat#M0262S / L).

[0190] BMX can include sequencing premix (Tris buffer, sodium chloride, sucrose, magnesium sulfate, EDTA and Tween20), ddNTP mixture, Pol19 DNA polymerase and TdT terminal transferase.

[0191] RSB may include Tris buffer, pH 8.5.

[0192] SPBs can include XP beads (Beckman Coulter, Cat# A63880). SPB should be vortexed before each use. SPB should be vortexed frequently to ensure even distribution of beads. Due to the viscosity of the solution, aspirate and disperse SPB slowly.

[0193] Some consumables should be stored and prepared as indicated in Table 2 below.

[0194] Table 2: Storage and preparation of consumables

[0195]

[0196] The following EMX program can be saved on the thermal cycler: (i) select preheat lid option and set to 100°C; (ii) 37°C for 30 min; (iii) 75°C for 10 min; and (iv) hold at 4°C.

[0197] The following BMX program can be saved on the thermal cycler: (i) select preheat lid option and set to 100°C; (ii) 38°C for 20 min; (iii) 60°C for 20 min; and (iv) hold at 4°C.

[0198] For 3' blocking treatment, samples can be processed as follows: (i) centrifuge BMX at 600×g for 5 seconds; (ii) add 30 μl of 5' protected DNA library sample pool to PCR tubes; (iii) add 30 μl BMX to each sample in each PCR tube and then mix thoroughly by pipetting up and down; (iv) incubate by placing on a thermal cycler and running the BMX program. Each tube contains 60 μl.

[0199] For 3' blocking plus exonuclease treatment, samples can be processed as follows: (i) EMX is centrifuged at 600×g for 5 seconds; (ii) 27 μl of the 5' protected DNA library sample pool is added to the PCR tube; (iii) 5 μl of EMX is added to each sample in each PCR tube and then mixed thoroughly by pipetting up and down; (iv) incubated by placing on a thermal cycler and running the EMX program; (v) BMX is centrifuged at 600×g for 5 seconds; (vi) 32 μl of BMX is added directly to each exonuclease reaction in each PCR tube and then mixed thoroughly by pipetting up and down; and (vii) incubated by placing on a thermal cycler and running the BMX program. Each tube contains 64 μl.

[0200] The processed pooled samples can be cleaned up as follows: (1) vortex SPB until well dispersed; (2) add 60 μl SPB to each sample processing tube and mix thoroughly by pipetting up and down; (3) incubate at room temperature for 5 minutes; (4) place on a magnetic stand and wait for the liquid to clarify (2 minutes to 5 minutes); (5) remove and discard all supernatant from each tube; (6) wash twice as follows: (a) add 200 μl of freshly prepared 80% EtOH to each tube, (b) incubate on a magnetic stand for 30 seconds, and (c) remove and discard all supernatant from each tube; (7) remove remaining EtOH from each tube using a 20 μl pipette; (8) air dry on a magnetic stand for 5 minutes; (9) add 22.5 μl Add RSB to each tube; (10) Remove from magnetic stand and then mix thoroughly by pipetting up and down; (11) Incubate at room temperature for 2 minutes; (12) Place on magnetic stand and wait for liquid to clear (2 minutes-5 minutes); (13) Transfer 20 μl of supernatant to a new tube; (14) If necessary, quantify the library and perform standard clustering for use starting with the NaOH denaturation step. 4000 platform; and (15) if not clustered immediately, stored at -25°C to -15°C.

[0201] Example 2: Reducing Index Jumping by 3' Blocking of 5' Protected Indexed Libraries

[0202] The processing protocol described in Example 1 above can be applied in combination with the following materials, equipment, and methods to facilitate clustering and sequencing on the Illumina platform.

[0203] Experimental conditions : (1) Human 450 bp NA12878 (Coriell Institute) generated using 5' protected P5 primer and P7 primer loaded at 300 pM Nanolibrary; (2) according to the manufacturer's instructions X instrument and Illumina SBS chemistry; (3) 550 nm ILS v3 flow cell; (4) ExAmp amplification as previously described; and (5) 50% adapter incorporation: free forked adapters from the Illumina Dual Adapter Plate (DAP) were spiked into the template library followed by denaturation, neutralization, addition of ExAmp mix, and clustering.

[0204] The results of this experiment are summarized in Tables 3 and Fig.10 middle.

[0205] Table 3: Reduction of index jumping by PCR protection with 3' block

[0206] library % Index Jump Standard adapter 2.4 5', 3' protected adapter 0.03 Protected adapter + exonuclease 0.023

[0207] As explained above, by using 5' protected and 3' blocked adapters as described herein, index jumping is significantly reduced relative to standard adapters. Optional exonuclease treatment can further reduce index jumping.

[0208] Any patent, patent application (whether published or not), or other document cited herein is hereby incorporated herein in whole or in part, to the extent it is not inconsistent with the disclosure presented herein.

[0209] In addition to the documents already cited in this application, reference is made here to three provisional patent applications (U.S. Provisional Application Nos. 62 / 488,824, 62 / 488,825, and 62 / 488,830, filed on April 23, 2017), which were filed on the same day as the provisional application to which this application claims priority, and are titled "Compositions and methods for improving sample identification in indexed nucleic acid libraries". The entire contents of these applications are also incorporated herein by reference.

[0210] It will be apparent to those skilled in the art that various modifications and variations may be made to the technology of the present invention without departing from the spirit and scope of the present invention. Because those skilled in the art may conceive of modifications, combinations, sub-combinations and variations of the disclosed embodiments that embody the spirit and essence of the technology of the present invention, the technology of the present invention should be understood to include all solutions within the scope of the appended claims and their equivalents.

[0211] This application also provides the following items:

[0212] 1. A method, comprising:

[0213] providing a first library comprising first one or more polynucleotides having a first adaptor-target-first adaptor sequence, wherein the polynucleotides of the first one or more polynucleotides are double-stranded in a region comprising the target and at least a portion of the first adaptor at both ends of the target;

[0214] providing a first primer oligonucleotide configured to hybridize to a portion of the first adaptor near the 3' end of a strand of the first adaptor, wherein the 5' end of the first primer oligonucleotide is modified to prevent digestion by an enzyme having 5' exonuclease activity;

[0215] providing a second primer oligonucleotide configured to hybridize to a complementary sequence of a portion of the first adaptor near the 3' end of a strand of the complementary sequence of the first adaptor, wherein the 5' end of the second primer oligonucleotide is modified to prevent digestion by an enzyme having 5' exonuclease activity;

[0216] incubating the first library with the first primer oligonucleotide and the second primer oligonucleotide in a solution under conditions suitable for amplifying the polynucleotide having a first adaptor-target-first adaptor sequence to produce an amplified first library polynucleotide having a 5' end modified to prevent digestion by an enzyme having 5' exonuclease activity, wherein the amplified polynucleotide has an amplified first adaptor-target-amplified first adaptor sequence, and wherein the amplified first adaptor sequence comprises a first library specific sequence;

[0217] The 3' end of the amplified first library polynucleotide is modified to prevent one or both of (i) or (ii): (i) digestion by an enzyme having 3' exonuclease activity, or (ii) addition of nucleotides to the 3' end by an enzyme having polymerase activity, thereby generating a protected first library polynucleotide having a modified 5' end and 3' end.

[0218] 2. The method according to item 1, wherein modifying the 3' end of the amplified first library polynucleotide comprises incorporating a dideoxynucleotide at the 3' end of the polynucleotide.

[0219] 3. The method according to item 1 or item 2, wherein the 5' end of the amplified first library polynucleotide comprises a phosphorothioate bond.

[0220] 4. The method according to item 1 or item 2, wherein the 5' end of the amplified first library polynucleotide contains three phosphorothioate bonds.

[0221] 5. The method according to any one of items 1 to 4, further comprising incubating the protected first library polynucleotide having a modified 3' end with one or more enzymes having 5' exonuclease activity and 3' exonuclease activity.

[0222] 6. The method according to any one of items 1 to 5, further comprising:

[0223] providing a substrate having a surface comprising more than one attached oligonucleotide having a free 3' end; and

[0224] The surface of the substrate is contacted with a composition comprising the protected first library polynucleotide having a modified 3' end under conditions that allow a portion of the strand of the first adaptor of the protected first library polynucleotide to hybridize to at least a portion of the oligonucleotide attached to the surface of the substrate.

[0225] 7. The method according to item 6 further comprises extending the oligonucleotide attached to the surface of the substrate from the free 3' end by incorporating nucleotides complementary to the sequence of the protected first library polynucleotide having the modified 3' end which hybridizes with the attached oligonucleotide to produce a copy of the hybridized polynucleotide so that the copy is attached to the surface of the substrate.

[0226] 8. The method according to item 7 further comprises amplifying the copies attached to the surface of the substrate.

[0227] 9. The method according to any one of items 1 to 7, further comprising:

[0228] providing a second library comprising second more than one polynucleotides having a second adaptor-target-second adaptor sequence, wherein the polynucleotides of the second more than one polynucleotides are double-stranded in a region comprising the target and at least a portion of the second adaptor at both ends of the target;

[0229] providing a third primer oligonucleotide configured to hybridize to a portion of the second adaptor near the 3' end of the strand of the second adaptor, wherein the 5' end of the third primer oligonucleotide is modified to prevent digestion by an enzyme having 5' exonuclease activity;

[0230] providing a fourth primer oligonucleotide configured to hybridize to a complementary sequence of a portion of the second adaptor near the 3' end of the strand of the complementary sequence of the second adaptor, wherein the 5' end of the fourth primer oligonucleotide is modified to prevent digestion by an enzyme having 5' exonuclease activity;

[0231] incubating the second library with the third primer oligonucleotide and the fourth primer oligonucleotide in a solution under conditions suitable for amplifying a polynucleotide having a second adaptor-target-second adaptor sequence to produce an amplified second library polynucleotide having a 5' end modified to prevent digestion by an enzyme having 5' exonuclease activity, wherein the amplified polynucleotide has an amplified second adaptor-target-amplified second adaptor sequence, and wherein the amplified second adaptor sequence comprises a second library specific sequence;

[0232] The 3' end of the amplified second library polynucleotide is modified to prevent one or both of (i) or (ii): (i) digestion by an enzyme having 3' exonuclease activity, or (ii) addition of nucleotides to the 3' end by an enzyme having polymerase activity, thereby generating a protected second library polynucleotide having a modified 5' end and 3' end.

[0233] 10. The method according to item 9, wherein modifying the 3' end of the amplified second library polynucleotide comprises incorporating a dideoxynucleotide at the 3' end of the polynucleotide.

[0234] 11. The method according to item 9 or item 10, wherein the 5' end of the amplified second library polynucleotide comprises a phosphorothioate bond.

[0235] 12. The method according to item 9 or item 10, wherein the 5' end of the amplified second library polynucleotide comprises three phosphorothioate bonds.

[0236] 13. The method according to any one of items 9 to 12, further comprising incubating the protected second library polynucleotide having a modified 3' end with one or more enzymes having 5' exonuclease activity and 3' exonuclease activity.

[0237] 14. A method according to any one of items 9 to 13, further comprising contacting the surface of the substrate with a composition comprising the protected second library polynucleotide having a modified 3' end under conditions allowing a portion of the chain of the second linker of the protected second library polynucleotide to hybridize with at least a portion of the oligonucleotide attached to the surface of the substrate.

[0238] 15. The method according to item 14 further comprises extending the oligonucleotide attached to the surface of the substrate from the free 3' end by incorporating nucleotides complementary to the sequence of the protected second library polynucleotide having the modified 3' end which hybridizes with the attached oligonucleotide to produce a copy of the hybridized polynucleotide so that the copy is attached to the surface of the substrate.

[0239] 16. The method according to item 15 further comprises amplifying the copies attached to the surface of the substrate.

[0240] 17. The method according to item 1, wherein the first adapter sequence comprises the first library-specific sequence.

[0241] 18. The method according to item 17, further comprising:

[0242] providing a second library comprising second more than one polynucleotides having a second adaptor-target-second adaptor sequence, wherein the second more than one polynucleotides are double-stranded in a region comprising the target and at least a portion of the second adaptor at either end of the target, wherein the second adaptor comprises a second library-specific sequence,

[0243] wherein the first primer oligonucleotide is configured to hybridize to a portion of the second adaptor near the 3' end of the strand of the second adaptor, and

[0244] wherein the second primer oligonucleotide is configured to hybridize to a complementary sequence of a portion of the second adaptor near the 3' end of a strand of the complementary sequence of the second adaptor; and

[0245] incubating the second library in the solution with the first library and the first primer oligonucleotide and the second primer oligonucleotide to amplify polynucleotides having the second adaptor-target-second adaptor sequence to produce amplified second library polynucleotides having 5' ends modified to prevent digestion by an enzyme having 5' exonuclease activity,

[0246] The method further comprises modifying the 3' end of the amplified second library polynucleotide to prevent one or both of (i) or (ii): (i) digestion by an enzyme having 3' exonuclease activity, or (ii) addition of nucleotides to the 3' end by an enzyme having polymerase activity, thereby producing a protected second library polynucleotide having a modified 5' end and 3' end.

[0247] 19. The method according to any one of items 1 to 18, further comprising incubating the composition comprising the protected first library polynucleotides having modified 5' and 3' ends with an exonuclease.

[0248] 20. A polynucleotide prepared for sequencing, the polynucleotide comprising

[0249] adapter-target-adapter sequence,

[0250] wherein the adaptor sequence comprises a library-specific sequence,

[0251] wherein the polynucleotide is double-stranded in a region comprising the target and at least a portion of the adaptor at both ends of the target, and

[0252] wherein the 5' end and the 3' end of the polynucleotide in the region of the adaptor sequence are single-stranded,

[0253] wherein the 5' end is modified to prevent digestion by an enzyme having 5' exonuclease activity, and

[0254] The 3' end is modified to inhibit one or both of (i) digestion by an enzyme having 3' exonuclease activity, or (ii) addition of nucleotides to the 3' end by an enzyme having polymerase activity.

[0255] 21. A composition comprising the polynucleotide according to item 20 and an exonuclease.

Claims

1. A method for preparing a library for multiplex sequencing, the method comprising: providing a first library comprising first one or more polynucleotides having a first adaptor-target-first adaptor sequence, wherein the polynucleotides of the first one or more polynucleotides are double-stranded in a region comprising the target and at least a portion of the first adaptor at both ends of the target; providing a first primer oligonucleotide configured to hybridize to a portion of the first adaptor near the 3' end of a strand of the first adaptor, wherein the 5' end of the first primer oligonucleotide is modified to prevent digestion by an enzyme having 5' exonuclease activity; providing a second primer oligonucleotide configured to hybridize to a complementary sequence of a portion of the first adaptor near the 3' end of a strand of the complementary sequence of the first adaptor, wherein the 5' end of the second primer oligonucleotide is modified to prevent digestion by an enzyme having 5' exonuclease activity; providing a second library comprising second more than one polynucleotides having a second adaptor-target-second adaptor sequence, wherein the polynucleotides of the second more than one polynucleotides are double-stranded in a region comprising the target and at least a portion of the second adaptor at both ends of the target; providing a third primer oligonucleotide configured to hybridize to a portion of the second adaptor near the 3' end of the strand of the second adaptor, wherein the 5' end of the third primer oligonucleotide is modified to prevent digestion by an enzyme having 5' exonuclease activity; providing a fourth primer oligonucleotide configured to hybridize to a complementary sequence of a portion of the second adaptor near the 3' end of the strand of the complementary sequence of the second adaptor, wherein the 5' end of the fourth primer oligonucleotide is modified to prevent digestion by an enzyme having 5' exonuclease activity; incubating the first library with the first primer oligonucleotide and the second primer oligonucleotide in a solution under conditions suitable for amplifying the first more than one polynucleotide having a first adaptor-target-first adaptor sequence to produce an amplified first library polynucleotide having a 5' end modified to prevent digestion by an enzyme having 5' exonuclease activity, wherein the amplified first library polynucleotide has an amplified first adaptor-target-amplified first adaptor sequence, and wherein the amplified first adaptor comprises a first library specific sequence; incubating the second library with the third primer oligonucleotide and the fourth primer oligonucleotide in solution under conditions suitable for amplifying a second more than one polynucleotide having a second adaptor-target-second adaptor sequence to produce an amplified second library polynucleotide having a 5' end modified to prevent digestion by an enzyme having 5' exonuclease activity, wherein the amplified second library polynucleotide has an amplified second adaptor-target-amplified second adaptor sequence, and wherein the amplified second adaptor comprises a second library specific sequence; Modifying the 3' end of the amplified first library polynucleotide to prevent one or both of (i) or (ii): (i) digestion by an enzyme having 3' exonuclease activity, or (ii) addition of nucleotides to the 3' end of the amplified first library polynucleotide by an enzyme having polymerase activity, thereby generating a protected first library polynucleotide having a modified 5' end and a modified 3' end; as well as Modifying the 3' end of the amplified second library polynucleotide to prevent one or both of (i) or (ii): (i) digestion by an enzyme having 3' exonuclease activity, or (ii) addition of nucleotides to the 3' end of the amplified second library polynucleotide by an enzyme having polymerase activity, thereby generating a protected second library polynucleotide having a modified 5' end and a modified 3' end; Wherein before said modification or after said modification, said first library and said second library are pooled.

2. A method for preparing a library for multiplex sequencing, the method comprising: providing a first library comprising first one or more polynucleotides having a first adaptor-target-first adaptor sequence, wherein the polynucleotides of the first one or more polynucleotides are double-stranded in a region comprising the target and at least a portion of the first adaptor at both ends of the target, and wherein the first adaptor comprises a first library-specific sequence; providing a second library comprising second more than one polynucleotides having a second adaptor-target-second adaptor sequence, wherein the second more than one polynucleotides are double-stranded in a region comprising the target and at least a portion of the second adaptor at either end of the target, wherein the second adaptor comprises a second library-specific sequence; providing a first primer oligonucleotide configured to (i) hybridize to a portion of the first adaptor near the 3' end of the strand of the first adaptor and (ii) hybridize to a portion of the second adaptor near the 3' end of the strand of the second adaptor, wherein the 5' end of the first primer oligonucleotide is modified to prevent digestion by an enzyme having 5' exonuclease activity; providing a second primer oligonucleotide configured to (i) hybridize to the complementary sequence of a portion of the first adaptor near the 3' end of the strand of the complementary sequence of the first adaptor and (ii) hybridize to the complementary sequence of a portion of the second adaptor near the 3' end of the strand of the complementary sequence of the second adaptor, wherein the 5' end of the second primer oligonucleotide is modified to prevent digestion by an enzyme having 5' exonuclease activity; incubating the first library and the second library with the first primer oligonucleotide and the second primer oligonucleotide in a solution under conditions suitable for amplifying the first more than one polynucleotide having a first adaptor-target-first adaptor sequence and the second more than one polynucleotide having a second adaptor-target-second adaptor sequence to produce amplified first library polynucleotides and amplified second library polynucleotides having 5' ends modified to prevent digestion by an enzyme having 5' exonuclease activity, wherein the amplified first library polynucleotides have an amplified first adaptor-target-amplified first adaptor sequence and the amplified second library polynucleotides have an amplified second adaptor-target-amplified second adaptor sequence; and The 3' end of the amplified first library polynucleotide and the amplified second library polynucleotide is modified to prevent one or both of (i) or (ii): (i) digestion by an enzyme having 3' exonuclease activity, or (ii) addition of nucleotides to the 3' end of the amplified first library polynucleotide or the amplified second library polynucleotide by an enzyme having polymerase activity, thereby generating a protected first library polynucleotide and a protected second library polynucleotide having modified 5' and 3' ends.

3. The method of claim 1 or 2, wherein modifying the 3' end of the amplified first library polynucleotide comprises incorporating a dideoxynucleotide at the 3' end of the amplified first library polynucleotide, and modifying the 3' end of the amplified second library polynucleotide comprises incorporating a dideoxynucleotide at the 3' end of the amplified second library polynucleotide.

4. The method of claim 1 or claim 2, wherein the 5' ends of the amplified first library polynucleotide and the amplified second library polynucleotide comprise phosphorothioate bonds.

5. The method of claim 1 or claim 2, wherein the 5' ends of the amplified first library polynucleotide and the amplified second library polynucleotide contain three phosphorothioate bonds.

6. The method according to claim 1 or 2, further comprising incubating the protected first library polynucleotide having a modified 3' end with one or more enzymes having 5' exonuclease activity and 3' exonuclease activity, and incubating the protected second library polynucleotide having a modified 3' end with one or more enzymes having 5' exonuclease activity and 3' exonuclease activity.

7. The method according to claim 1 or 2, further comprising: providing a substrate having a surface comprising more than one attached oligonucleotide having a free 3' end; and The surface of the substrate is contacted with a composition comprising the pooled protected first library polynucleotides having a modified 3' end and the protected second library polynucleotides having a modified 3' end under conditions that allow a portion of the chains of the first adaptor of the protected first library polynucleotides and the second adaptor of the protected second library polynucleotides to hybridize to at least a portion of the oligonucleotides attached to the surface of the substrate.

8. The method of claim 7, further comprising extending the oligonucleotide attached to the surface of the substrate from the free 3' end by incorporating nucleotides complementary to the sequence of the protected first library polynucleotide having the modified 3' end that hybridizes to the attached oligonucleotide and the protected second library polynucleotide having the modified 3' end that hybridizes to the attached oligonucleotide to produce a copy of the hybridized protected first library polynucleotide and a copy of the hybridized protected second library polynucleotide such that the copies are attached to the surface of the substrate.

9. The method of claim 8, further comprising amplifying the copies attached to the surface of the substrate.

10. The method of claim 1 or 2, further comprising incubating the composition comprising the protected first library polynucleotide having modified 5' and 3' ends and the protected second library polynucleotide with an exonuclease.

11. A polynucleotide prepared for sequencing, the polynucleotide comprising adapter-target-adapter sequence, wherein the adaptor comprises a library-specific sequence, wherein the polynucleotide is double-stranded in a region comprising the target and at least a portion of the adaptor at both ends of the target, and wherein the 5' end and the 3' end of the polynucleotide in the region of the adaptor are single-stranded, wherein the 5' end is modified to prevent digestion by an enzyme having 5' exonuclease activity, and The 3' end is modified to inhibit one or both of (i) digestion by an enzyme having 3' exonuclease activity, or (ii) addition of nucleotides to the 3' end by an enzyme having polymerase activity.

12. A composition comprising the polynucleotide according to claim 11 and an exonuclease.